ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
AC   Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4;
AC   Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2;
AC   Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   29-MAY-2013, entry version 209.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4006916;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-76.
RX   PubMed=2946935;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3894933;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3025664;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA   Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA   Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the
RT   human p53 gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   PubMed=1915267;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=8316628;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND
RP   SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139
RP   AND PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   PubMed=6396087;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA   Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression
RT   of the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism
RT   patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated
RT   with cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification
RT   of the p53 gene from microdissected tissue: application to archival
RT   tumor samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [27]
RP   NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND
RP   LYS-321.
RX   PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a
RT   p34cdc2 kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [28]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [29]
RP   PHOSPHORYLATION.
RX   PubMed=1705009;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
RT   linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [30]
RP   DEPHOSPHORYLATION BY PP2A.
RX   PubMed=1848668;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT   by protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [31]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in
RT   normal cells.";
RL   Oncogene 12:813-818(1996).
RN   [32]
RP   GLYCOSYLATION.
RX   PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [33]
RP   PHOSPHORYLATION AT SER-33.
RX   PubMed=9372954;
RA   Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y.,
RA   Prives C., Pan Z.-Q.;
RT   "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent
RT   manner.";
RL   Mol. Cell. Biol. 17:7220-7229(1997).
RN   [34]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK.
RX   PubMed=9840937; DOI=10.1038/sj.onc.1202504;
RA   Schneider E., Montenarh M., Wagner P.;
RT   "Regulation of CAK kinase activity by p53.";
RL   Oncogene 17:2733-2741(1998).
RN   [35]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-
RT   1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [36]
RP   PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1.
RX   PubMed=10606744; DOI=10.1016/S0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [37]
RP   BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT
RP   ASN-305.
RX   PubMed=10551826; DOI=10.1074/jbc.274.46.32699;
RA   Liang S.H., Clarke M.F.;
RT   "A bipartite nuclear localization signal is required for p53 nuclear
RT   import regulated by a carboxyl-terminal domain.";
RL   J. Biol. Chem. 274:32699-32703(1999).
RN   [38]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20
RP   AND 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND
RP   MDM2.
RX   PubMed=10570149; DOI=10.1073/pnas.96.24.13777;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [40]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to
RT   ionizing radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [41]
RP   PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF
RP   LYS-382; LEU-383 AND PHE-385.
RX   PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
RA   Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
RT   "The C-terminal regulatory domain of p53 contains a functional docking
RT   site for cyclin A.";
RL   J. Mol. Biol. 300:503-518(2000).
RN   [42]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [43]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [44]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [45]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [46]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [47]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [48]
RP   MINIMAL REPRESSION DOMAIN.
RX   PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression
RT   domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [49]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11447225; DOI=10.1074/jbc.M104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20
RT   is mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [50]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11551930; DOI=10.1074/jbc.M106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C.,
RA   Stambrook P., Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis
RT   at least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [51]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PHE-385; LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.M009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification
RT   motif and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [52]
RP   PHOSPHORYLATION BY PRPK.
RX   PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase
RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT   tumor cell lines, and the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [53]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [54]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/S0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E.,
RA   Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in
RT   isolation and in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [55]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [56]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [57]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [58]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA   Fanciulli M., Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT   and mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [59]
RP   INTERACTION WITH ING4.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [60]
RP   ACETYLATION AT LYS-305.
RX   PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [61]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.M301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [62]
RP   INTERACTION WITH TP53INP1.
RX   PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [63]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   PubMed=12944468; DOI=10.1128/MCB.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [64]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [65]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/BJ20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for
RT   a novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [66]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [67]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [68]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [69]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/MCB.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [70]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A.,
RA   Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [71]
RP   INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated
RT   destabilization and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [72]
RP   INTERACTION WITH NOC2L.
RX   PubMed=16322561; DOI=10.1101/gad.351205;
RA   Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N.,
RA   Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A.,
RA   Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.;
RT   "NIR is a novel INHAT repressor that modulates the transcriptional
RT   activity of p53.";
RL   Genes Dev. 19:2912-2924(2005).
RN   [73]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.M413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its
RT   arginine-serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [74]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=15855171; DOI=10.1074/jbc.M414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase
RT   with the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [75]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [76]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [77]
RP   INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND
RP   SER-392.
RX   PubMed=17108107; DOI=10.1158/0008-5472.CAN-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [78]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2)
RT   isoforms determines their different effect on p53 stability in tumour
RT   cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [79]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [80]
RP   PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG.
RX   PubMed=16377624; DOI=10.1074/jbc.M512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [81]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [82]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [83]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [84]
RP   PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [85]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y.,
RA   Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K.,
RA   Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S.,
RA   Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H.,
RA   Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A.,
RA   Nishioka K., Tanaka K., Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [86]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [87]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [88]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [89]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [90]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.M608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y.,
RA   Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A.,
RA   Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L.,
RA   Wu L., Griffin J.D., Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [91]
RP   PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [92]
RP   FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [93]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [94]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine
RT   382.";
RL   Mol. Cell 27:636-646(2007).
RN   [95]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [96]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-
RT   enhanced p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [97]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT
RP   SER-15 BY ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/MCB.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with
RT   B56gamma and the tumor suppressor activity of B56gamma-specific
RT   protein phosphatase 2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [98]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND
RP   UBIQUITINATION AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls
RT   cell cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [99]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [100]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=19776115; DOI=10.1128/JVI.00304-09;
RA   Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y.,
RA   Huang E.S.;
RT   "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits
RT   p53-dependent transactivation by a mechanism different from that of
RT   IE2-86 protein.";
RL   J. Virol. 83:12388-12398(2009).
RN   [101]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y.,
RA   Li R., Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex
RT   to p53 regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [102]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [103]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [104]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating
RT   p53.";
RL   Cell 140:384-396(2010).
RN   [105]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M.,
RA   Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [106]
RP   PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [107]
RP   INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155;
RP   HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF
RP   ARG-248.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein
RT   in hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [108]
RP   INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.M109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism
RT   facilitating cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [109]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.M109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [110]
RP   ERRATUM.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [111]
RP   PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5.
RX   PubMed=20124405; DOI=10.1074/jbc.M109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits
RT   DNA damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [112]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53
RT   function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [113]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [114]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and
RT   BAF180 are critical regulators of p53 required for induction of
RT   replicative senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [115]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [116]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [117]
RP   FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT
RP   SER-183; SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284,
RP   MUTAGENESIS OF SER-183 AND SER-269, AND MASS SPECTROMETRY.
RX   PubMed=20959462; DOI=10.1074/jbc.M110.174755;
RA   Wu L., Ma C.A., Zhao Y., Jain A.;
RT   "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in
RT   its DNA-binding domain and subsequent functional suppression.";
RL   J. Biol. Chem. 286:2236-2244(2011).
RN   [118]
RP   INVOLVEMENT IN BCC7.
RX   PubMed=21946351; DOI=10.1038/ng.926;
RA   Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J.,
RA   Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A.,
RA   Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K.,
RA   Hemminki K., Corredera C., Fuentelsaz V., Grasa P., Navarrete S.,
RA   Fuertes F., Garcia-Prats M.D., Sanambrosio E., Panadero A.,
RA   De Juan A., Garcia A., Rivera F., Planelles D., Soriano V.,
RA   Requena C., Aben K.K., van Rossum M.M., Cremers R.G., van Oort I.M.,
RA   van Spronsen D.J., Schalken J.A., Peters W.H., Helfand B.T.,
RA   Donovan J.L., Hamdy F.C., Badescu D., Codreanu O., Jinga M.,
RA   Csiki I.E., Constantinescu V., Badea P., Mates I.N., Dinu D.E.,
RA   Constantin A., Mates D., Kristjansdottir S., Agnarsson B.A.,
RA   Jonsson E., Barkardottir R.B., Einarsson G.V., Sigurdsson F.,
RA   Moller P.H., Stefansson T., Valdimarsson T., Johannsson O.T.,
RA   Sigurdsson H., Jonsson T., Jonasson J.G., Tryggvadottir L., Rice T.,
RA   Hansen H.M., Xiao Y., Lachance D.H., O'Neill B.P., Kosel M.L.,
RA   Decker P.A., Thorleifsson G., Johannsdottir H., Helgadottir H.T.,
RA   Sigurdsson A., Steinthorsdottir V., Lindblom A., Sandler R.S.,
RA   Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T.,
RA   Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M.,
RA   Wiencke J., Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A.,
RA   Kumar R., Mayordomo J.I., Olafsson J.H., Kong A., Thorsteinsdottir U.,
RA   Rafnar T., Stefansson K.;
RT   "A germline variant in the TP53 polyadenylation signal confers cancer
RT   susceptibility.";
RL   Nat. Genet. 43:1098-1103(2011).
RN   [119]
RP   INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [120]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [121]
RP   INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT
RP   LYS-386.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [122]
RP   INTERACTION WITH ZNF385B.
RX   PubMed=22945289; DOI=10.1002/eji.201242530;
RA   Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S.,
RA   Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J.,
RA   Kiyokawa N.;
RT   "ZNF385B is characteristically expressed in germinal center B cells
RT   and involved in B-cell apoptosis.";
RL   Eur. J. Immunol. 42:3405-3415(2012).
RN   [123]
RP   METHYLATION AT LYS-370 AND LYS-382.
RX   PubMed=22864287; DOI=10.1038/nsmb.2353;
RA   Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F.,
RA   Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.;
RT   "PHF20 is an effector protein of p53 double lysine methylation that
RT   stabilizes and activates p53.";
RL   Nat. Struct. Mol. Biol. 19:916-924(2012).
RN   [124]
RP   INTERACTION WITH KAT6A, AND ACETYLATION AT LYS-120 AND LYS-382.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I.,
RA   Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its
RT   complex formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 0:0-0(2013).
RN   [125]
RP   STRUCTURE BY NMR OF 319-360.
RX   PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [126]
RP   STRUCTURE BY NMR OF 325-355.
RX   PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of
RT   p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [127]
RP   STRUCTURE BY NMR OF 326-354.
RX   PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [128]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
RT   understanding tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [129]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [130]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [131]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [132]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS, AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.M309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [133]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [134]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [135]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH
RP   USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION
RP   WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [136]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT
RP   LYS-382, MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.M110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at
RT   lysine 382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [137]
RP   REVIEW.
RX   PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk
RT   assessment.";
RL   Science 262:1980-1981(1993).
RN   [138]
RP   REVIEW ON VARIANTS.
RX   PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [139]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829653;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes
RT   designed to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [140]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and
RT   designing rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [141]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/S0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of
RT   p53 DNA-binding domain as revealed by crystallography at 1.54
RT   angstroms resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [142]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J.,
RA   Veprintsev D.B., Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico
RT   screened drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [143]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N.,
RA   Shimon L.J., Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [144]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [145]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the
RT   surface of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [146]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures
RT   with Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [147]
RP   VARIANT ARG-72.
RX   PubMed=1999338; DOI=10.1007/BF00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of
RT   the Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [148]
RP   VARIANT LFS THR-133.
RX   PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [149]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA   Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
RT   sarcomas, and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [150]
RP   VARIANT LFS ASP-245.
RX   PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT   with Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [151]
RP   VARIANT LFS LEU-272.
RX   PubMed=1737852; DOI=10.1172/JCI115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA   Knutsen T., Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [152]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   PubMed=1565144;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA   Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and
RT   young adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [153]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast
RT   cancer cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [154]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [155]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND
RP   SER-278.
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [156]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1647768; DOI=10.1016/0006-291X(91)90623-F;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [157]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP   HIS-273.
RX   PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA   Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [158]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular
RT   carcinomas.";
RL   Nature 350:427-428(1991).
RN   [159]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT   from southern Africa.";
RL   Nature 350:429-431(1991).
RN   [160]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND
RP   HIS-273.
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [161]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1327751;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary
RT   cervical cancers suggest mechanisms of metastasis and involvement of
RT   environmental carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [162]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [163]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [164]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization
RT   relative to other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [165]
RP   VARIANT SPORADIC CANCER THR-280.
RX   PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y.,
RA   Chen I.-H., Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [166]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [167]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and
RT   neck cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [168]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [169]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A.,
RA   Kelsey A.M., Harris M., Jones P.H., Binchy A., Crowther D.,
RA   Craft A.W., Eden O.B., Evans D.G.R., Thompson E., Mann J.R.,
RA   Martin J., Mitchell E.L.D., Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene
RT   among 21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [170]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   PubMed=8013454;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [171]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [172]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [173]
RP   VARIANT LFS HIS-175.
RX   PubMed=8825920;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA   Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT   175 mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [174]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND
RP   GLN-286.
RX   PubMed=8829627;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [175]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=9101296;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
RT   to genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [176]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [177]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP   AND SER-278.
RX   PubMed=9450901;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [178]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   PubMed=9452042;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [179]
RP   VARIANT LFS ILE-292.
RX   PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT   a Li-Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [180]
RP   VARIANTS.
RX   PubMed=10549356;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [181]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P.,
RA   Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C.,
RA   Sampaio G., Cat I., Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific
RT   manner to pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [182]
RP   INVOLVEMENT IN CPLPA.
RX   PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel
RT   germline p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [183]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248;
RP   SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280
RP   AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [184]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195;
RP   MET-216; ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [185]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V.,
RA   Hainaut P., Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns
RT   and tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Implicated in Notch signaling cross-over.
CC       Prevents CDK7 kinase activity when associated to CAK complex in
CC       response to DNA damage, thus stopping cell cycle progression.
CC       Isoform 2 enhances the transactivation activity of isoform 1 from
CC       some but not all TP53-inducible promoters. Isoform 4 suppresses
CC       transactivation activity and impairs growth suppression mediated
CC       by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
CC       a homotetramer. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. In vitro, the interaction of TP53 with cancer-
CC       associated/HPV (E6) viral proteins leads to ubiquitination and
CC       degradation of TP53 giving a possible model for cell growth
CC       regulation. This complex formation requires an additional factor,
CC       E6-AP, which stably associates with TP53 in the presence of E6.
CC       Interacts (via C-terminus) with TAF1; when TAF1 is part of the
CC       TFIID complex. Interacts with ING4; this interaction may be
CC       indirect. Found in a complex with CABLES1 and TP73. Interacts with
CC       HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with
CC       HCV core protein. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and
CC       prevent transactivation activity (By similarity). Interacts with
CC       ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1.
CC       Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58'
CC       inhibits this interaction. Interacts (via DNA-binding domain) with
CC       MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML
CC       (via C-terminus). Interacts with MDM2; leading to ubiquitination
CC       and proteasomal degradation of TP53. Directly interacts with
CC       FBXO42; leading to ubiquitination and degradation of TP53.
CC       Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase
CC       PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent
CC       inhibition of cell proliferation. Interacts with PPP2R2A.
CC       Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when
CC       monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with
CC       isoform 2 and with isoform 4. Interacts with GRK5. Binds to the
CC       CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, UHRF2 and
CC       NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF;
CC       the association implicates preferentially tetrameric TP53, is
CC       induced by oxidative stress and is impaired by cyclosporin A
CC       (CsA). Interacts with human cytomegalovirus/HHV-5 protein UL123.
CC       Interacts with SNAI1; the interaction induces SNAI1 degradation
CC       via MDM2-mediated ubiquitination and inhibits SNAI1-induced cell
CC       invasion. Interacts with KAT6A. Interacts with UBC9. Forms a
CC       complex with UBC9 and PRKRA. Interacts with ZNF385B; the
CC       interaction is direct.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-366083, EBI-366083;
CC       P03070:- (xeno); NbExp=6; IntAct=EBI-366083, EBI-617698;
CC       O15169:AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484;
CC       P10415:BCL2; NbExp=3; IntAct=EBI-366083, EBI-77694;
CC       Q07817-1:BCL2L1; NbExp=18; IntAct=EBI-366083, EBI-287195;
CC       Q9NPI1:BRD7; NbExp=8; IntAct=EBI-366083, EBI-711221;
CC       Q9BX70:BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091;
CC       Q9ESJ1:Cables1 (xeno); NbExp=3; IntAct=EBI-366083, EBI-604411;
CC       P17676:CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696;
CC       Q92793:CREBBP; NbExp=6; IntAct=EBI-366083, EBI-81215;
CC       P45481:Crebbp (xeno); NbExp=6; IntAct=EBI-366083, EBI-296306;
CC       P55060:CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709;
CC       Q14999:CUL7; NbExp=3; IntAct=EBI-366083, EBI-308606;
CC       Q8IWT3:CUL9; NbExp=2; IntAct=EBI-366083, EBI-311123;
CC       Q9UER7:DAXX; NbExp=11; IntAct=EBI-366083, EBI-77321;
CC       Q92841:DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012;
CC       P17844:DDX5; NbExp=3; IntAct=EBI-366083, EBI-351962;
CC       Q9BV47:DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519;
CC       Q09472:EP300; NbExp=7; IntAct=EBI-366083, EBI-447295;
CC       Q86XK2:FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804;
CC       Q13547:HDAC1; NbExp=3; IntAct=EBI-366083, EBI-301834;
CC       Q86Z02:HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891;
CC       Q9BUJ2:HNRNPUL1; NbExp=11; IntAct=EBI-366083, EBI-1018153;
CC       P38646:HSPA9; NbExp=2; IntAct=EBI-366083, EBI-354932;
CC       P42858:HTT; NbExp=4; IntAct=EBI-366083, EBI-466029;
CC       Q7Z6Z7:HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934;
CC       Q16666-2:IFI16; NbExp=3; IntAct=EBI-366083, EBI-6273540;
CC       Q92993:KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080;
CC       P43356:MAGEA2; NbExp=6; IntAct=EBI-366083, EBI-5650739;
CC       Q9UBF1:MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487;
CC       Q15759:MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304;
CC       Q8IW41:MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460;
CC       Q00987:MDM2; NbExp=29; IntAct=EBI-366083, EBI-389668;
CC       O15151:MDM4; NbExp=4; IntAct=EBI-366083, EBI-398437;
CC       Q8IZD2:MLL5; NbExp=4; IntAct=EBI-366083, EBI-2689959;
CC       P23511:NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739;
CC       Q9Y3T9:NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547;
CC       P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579;
CC       P06748-1:NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150;
CC       O60285:NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789;
CC       P09874:PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676;
CC       Q96KB5:PBK; NbExp=7; IntAct=EBI-366083, EBI-536853;
CC       O75925:PIAS1; NbExp=3; IntAct=EBI-366083, EBI-629434;
CC       Q8N2W9:PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160;
CC       Q13526:PIN1; NbExp=11; IntAct=EBI-366083, EBI-714158;
CC       P29590:PML; NbExp=3; IntAct=EBI-366083, EBI-295890;
CC       P30405:PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229;
CC       P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       Q8WUF5:PPP1R13L; NbExp=3; IntAct=EBI-366083, EBI-5550163;
CC       Q05397:PTK2; NbExp=11; IntAct=EBI-366083, EBI-702142;
CC       Q06609:RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202;
CC       Q8WTS6:SETD7; NbExp=6; IntAct=EBI-366083, EBI-1268586;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       Q96EB6:SIRT1; NbExp=13; IntAct=EBI-366083, EBI-1802965;
CC       Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-1802585;
CC       Q12772:SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059;
CC       P20226:TBP; NbExp=2; IntAct=EBI-366083, EBI-355371;
CC       Q9H3D4:TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775;
CC       O88898:Tp63 (xeno); NbExp=2; IntAct=EBI-366083, EBI-2338025;
CC       Q15672:TWIST1; NbExp=9; IntAct=EBI-366083, EBI-1797287;
CC       P26687:Twist1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-6123119;
CC       Q05086:UBE3A; NbExp=2; IntAct=EBI-366083, EBI-954357;
CC       Q96PU4:UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304;
CC       Q93009:USP7; NbExp=10; IntAct=EBI-366083, EBI-302474;
CC       P11473:VDR; NbExp=6; IntAct=EBI-366083, EBI-286357;
CC       Q14191:WRN; NbExp=5; IntAct=EBI-366083, EBI-368417;
CC       P12956:XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208;
CC       Q9PST7:znf585b (xeno); NbExp=3; IntAct=EBI-366083, EBI-1782562;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with
CC       BANP promotes nuclear localization. Recruited into PML bodies
CC       together with CHEK2. Translocates to mitochondria upon oxidative
CC       stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm.
CC       Note=Localized in the nucleus in most cells but found in the
CC       cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm
CC       following cell stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm.
CC       Note=Localized in both nucleus and cytoplasm in most cells. In
CC       some cells, forms foci in the nucleus that are different from
CC       nucleoli.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC         Note=Produced by alternative promoter usage;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide
CC       range of normal tissues but in a tissue-dependent manner. Isoform
CC       2 is expressed in most normal tissues but is not detected in
CC       brain, lung, prostate, muscle, fetal brain, spinal cord and fetal
CC       liver. Isoform 3 is expressed in most normal tissues but is not
CC       detected in lung, spleen, testis, fetal brain, spinal cord and
CC       fetal liver. Isoform 7 is expressed in most normal tissues but is
CC       not detected in prostate, uterus, skeletal muscle and breast.
CC       Isoform 8 is detected only in colon, bone marrow, testis, fetal
CC       brain and intestine. Isoform 9 is expressed in most normal tissues
CC       but is not detected in brain, heart, lung, fetal liver, salivary
CC       gland, breast or intestine.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is
CC       not induced in tumor cells in response to stress.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
CC       repression domain. The TADI and TADII motifs (residues 17 to 25
CC       and 48 to 56) correspond both to 9aaTAD motifs which are
CC       transactivation domains present in a large number of yeast and
CC       animal transcription factors.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
CC       impairs its ability to induce proapoptotic program and modulate
CC       cell senescence.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity).
CC       Phosphorylation at Ser-9 by HIPK4 increases repression activity on
CC       BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated
CC       on Ser-20 by CHEK2 in response to DNA damage, which prevents
CC       ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in
CC       response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which
CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by
CC       CDK7 in a CAK complex in response to DNA damage. Phosphorylated on
CC       Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is
CC       required for acetylation by CREBBP. Phosphorylated on Ser-392
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was
CC       intially thought to be mediated by STK11/LKB1 but it was later
CC       shown that it is indirect and that STK11/LKB1-dependent
CC       phosphorylation is probably mediated by downstream NUAK1
CC       (PubMed:21317932). It is unclear whether AMP directly mediates
CC       phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1
CC       and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of
CC       VRK2 results in a reduction in ubiquitination by MDM2 and an
CC       increase in acetylation by EP300. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40
CC       small T antigen inhibits the dephosphorylation by the AC form of
CC       PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
CC       in EB-1 cell line.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to its
CC       stabilization. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilization. Isoform 4 is
CC       monoubiquitinated in an MDM2-independent manner.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Dimethylation at Lys-370 and Lys-382 diminishes p53
CC       ubiquitination, through stabilizing association with the methyl
CC       reader PHF20. Demethylation of dimethylated Lys-370 by KDM1A
CC       prevents interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety
CC       of transformed cells. TP53 is frequently mutated or inactivated in
CC       about 60% of cancers. TP53 defects are found in Barrett metaplasia
CC       a condition in which the normally stratified squamous epithelium
CC       of the lower esophagus is replaced by a metaplastic columnar
CC       epithelium. The condition develops as a complication in
CC       approximately 10% of patients with chronic gastroesophageal reflux
CC       disease and predisposes to the development of esophageal
CC       adenocarcinoma.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal
CC       dominant familial cancer syndrome that in its classic form is
CC       defined by the existence of a proband affected by a sarcoma before
CC       45 years with a first degree relative affected by any tumor before
CC       45 years and another first degree relative with any tumor before
CC       45 years or a sarcoma at any age. Other clinical definitions for
CC       LFS have been proposed (PubMed:8118819 and PubMed:8718514) and
CC       called Li-Fraumeni like syndrome (LFL). In these families affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. Four types of cancers account for 80% of tumors occurring in
CC       TP53 germline mutation carriers: breast cancers, soft tissue and
CC       bone sarcomas, brain tumors (astrocytomas) and adrenocortical
CC       carcinomas. Less frequent tumors include choroid plexus carcinoma
CC       or papilloma before the age of 15, rhabdomyosarcoma before the age
CC       of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal
CC       and gastric cancers. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and
CC       neck. The hallmark of cutaneous SCC is malignant transformation of
CC       normal epidermal keratinocytes. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Choroid plexus papilloma (CPLPA) [MIM:260500]: Slow-
CC       growing benign tumor of the choroid plexus that often invades the
CC       leptomeninges. In children it is usually in a lateral ventricle
CC       but in adults it is more often in the fourth ventricle.
CC       Hydrocephalus is common, either from obstruction or from tumor
CC       secretion of cerebrospinal fluid. If it undergoes malignant
CC       transformation it is called a choroid plexus carcinoma. Primary
CC       choroid plexus tumors are rare and usually occur in early
CC       childhood. Note=The disease is caused by mutations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant
CC       neoplasm of the adrenal cortex and a rare childhood tumor. It
CC       occurs with increased frequency in patients with Beckwith-
CC       Wiedemann syndrome and Li-Fraumeni syndrome. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common
CC       malignant skin neoplasm that typically appears on hair-bearing
CC       skin, most commonly on sun-exposed areas. It is slow growing and
CC       rarely metastasizes, but has potentialities for local invasion and
CC       destruction. It usually develops as a flat, firm, pale area that
CC       is small, raised, pink or red, translucent, shiny, and waxy, and
CC       the area may bleed following minor injury. Tumor size can vary
CC       from a few millimeters to several centimeters in diameter.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="http://www-p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=The TP53 mutant web site; Note=TP53 mutations
CC       and cancer;
CC       URL="http://p53.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TP53";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="http://en.wikipedia.org/wiki/P53";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   IPI; IPI00025087; -.
DR   IPI; IPI00375319; -.
DR   IPI; IPI00796188; -.
DR   IPI; IPI00894418; -.
DR   IPI; IPI00895905; -.
DR   IPI; IPI00973801; -.
DR   IPI; IPI01008713; -.
DR   IPI; IPI01009016; -.
DR   IPI; IPI01009039; -.
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.5.
DR   RefSeq; NP_001119584.1; NM_001126112.2.
DR   RefSeq; NP_001119585.1; NM_001126113.2.
DR   RefSeq; NP_001119586.1; NM_001126114.2.
DR   RefSeq; NP_001119587.1; NM_001126115.1.
DR   RefSeq; NP_001119588.1; NM_001126116.1.
DR   RefSeq; NP_001119589.1; NM_001126117.1.
DR   RefSeq; NP_001119590.1; NM_001126118.1.
DR   RefSeq; NP_001263624.1; NM_001276695.1.
DR   RefSeq; NP_001263625.1; NM_001276696.1.
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1.
DR   RefSeq; NP_001263690.1; NM_001276761.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=363-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=332-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2LY4; NMR; -; B=1-93.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2QVQ; X-ray; 2.00 A; A=94-289.
DR   PDB; 2QXA; X-ray; 1.50 A; A/B/C/D=95-289.
DR   PDB; 2QXB; X-ray; 2.50 A; A/B/C/D=95-289.
DR   PDB; 2QXC; X-ray; 1.85 A; A/B/C/D=95-289.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-312.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2XWR; X-ray; 1.68 A; A/B=89-293.
DR   PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3Q01; X-ray; 2.10 A; A/B=94-356.
DR   PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-355.
DR   PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 3TG5; X-ray; 2.30 A; B=365-375.
DR   PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-355.
DR   PDB; 4AGL; X-ray; 1.70 A; A/B=94-312.
DR   PDB; 4AGM; X-ray; 1.52 A; A/B=94-312.
DR   PDB; 4AGN; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 4AGO; X-ray; 1.45 A; A/B=94-312.
DR   PDB; 4AGP; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2QVQ; -.
DR   PDBsum; 2QXA; -.
DR   PDBsum; 2QXB; -.
DR   PDBsum; 2QXC; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2XWR; -.
DR   PDBsum; 2YBG; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3OQ5; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3Q01; -.
DR   PDBsum; 3Q05; -.
DR   PDBsum; 3Q06; -.
DR   PDBsum; 3SAK; -.
DR   PDBsum; 3TG5; -.
DR   PDBsum; 3TS8; -.
DR   PDBsum; 4AGL; -.
DR   PDBsum; 4AGM; -.
DR   PDBsum; 4AGN; -.
DR   PDBsum; 4AGO; -.
DR   PDBsum; 4AGP; -.
DR   PDBsum; 4AGQ; -.
DR   DisProt; DP00086; -.
DR   ProteinModelPortal; P04637; -.
DR   SMR; P04637; 13-61, 91-356.
DR   DIP; DIP-368N; -.
DR   IntAct; P04637; 190.
DR   MINT; MINT-91013; -.
DR   PhosphoSite; P04637; -.
DR   DMDM; 269849759; -.
DR   SWISS-2DPAGE; P04637; -.
DR   PaxDb; P04637; -.
DR   PRIDE; P04637; -.
DR   DNASU; 7157; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510.
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510.
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510.
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gih.3; human.
DR   UCSC; uc010cnf.1; human.
DR   UCSC; uc010cng.1; human.
DR   UCSC; uc010cnh.1; human.
DR   UCSC; uc010cni.1; human.
DR   CTD; 7157; -.
DR   GeneCards; GC17M007565; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; CAB002973; -.
DR   HPA; CAB039238; -.
DR   HPA; CAB039239; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 614740; phenotype.
DR   neXtProt; NX_P04637; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   PharmGKB; PA36679; -.
DR   eggNOG; NOG80479; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P04637; -.
DR   KO; K04451; -.
DR   OMA; SQKTYPG; -.
DR   OrthoDB; EOG45757H; -.
DR   PhylomeDB; P04637; -.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; bard1pathway; BARD1 signaling events.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; hif1apathway; Hypoxic and oxygen homeostasis regulation of HIF-1-alpha.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; hdac_classiii_pathway; Signaling events mediated by HDAC Class III.
DR   Pathway_Interaction_DB; p38alphabetadownstreampathway; Signaling mediated by p38-alpha and p38-beta.
DR   Reactome; REACT_115566; Cell Cycle.
DR   Reactome; REACT_604; Hemostasis.
DR   SignaLink; P04637; -.
DR   BindingDB; P04637; -.
DR   ChEMBL; CHEMBL4096; -.
DR   ChiTaRS; TP53; human.
DR   EvolutionaryTrace; P04637; -.
DR   GenomeRNAi; 7157; -.
DR   NextBio; 28006; -.
DR   PMAP-CutDB; P04637; -.
DR   ArrayExpress; P04637; -.
DR   Bgee; P04637; -.
DR   Genevestigator; P04637; -.
DR   GermOnline; ENSG00000141510; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:BHF-UCL.
DR   GO; GO:0005657; C:replication fork; IBA:RefGenome.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:RefGenome.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Compara.
DR   GO; GO:0002039; F:p53 binding; IBA:RefGenome.
DR   GO; GO:0001077; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; IEA:Compara.
DR   GO; GO:0001228; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; IDA:BHF-UCL.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Compara.
DR   GO; GO:0006284; P:base-excision repair; TAS:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IBA:RefGenome.
DR   GO; GO:0007417; P:central nervous system development; IEA:Compara.
DR   GO; GO:0051276; P:chromosome organization; IEA:Compara.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IMP:BHF-UCL.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IEA:Compara.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0007369; P:gastrulation; IEA:Compara.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Compara.
DR   GO; GO:0006917; P:induction of apoptosis; IEA:Compara.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Compara.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Compara.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IEA:Compara.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Compara.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Compara.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Compara.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0090343; P:positive regulation of cell aging; IEA:Compara.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:RefGenome.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:RefGenome.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IEA:Compara.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; TAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; TAS:UniProtKB.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Compara.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0009651; P:response to salt stress; IEA:Compara.
DR   GO; GO:0010165; P:response to X-ray; IBA:RefGenome.
DR   GO; GO:0009303; P:rRNA transcription; IEA:Compara.
DR   GO; GO:0001756; P:somitogenesis; IEA:Compara.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Compara.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Compara.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Compara.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Compara.
DR   GO; GO:0019048; P:virus-host interaction; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   SUPFAM; SSF47719; p53_tetrameristn; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; Disease mutation; DNA-binding; Endoplasmic reticulum;
KW   Glycoprotein; Host-virus interaction; Isopeptide bond;
KW   Li-Fraumeni syndrome; Metal-binding; Methylation; Mitochondrion;
KW   Necrosis; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transcription; Transcription regulation; Tumor suppressor;
KW   Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185703.
FT   DNA_BIND    102    292
FT   REGION        1     83       Interaction with HRMT1L2.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX.
FT   REGION      100    370       Interaction with HIPK1 (By similarity).
FT   REGION      113    236       Required for interaction with FBXO42.
FT   REGION      116    292       Interaction with AXIN1 (By similarity).
FT   REGION      241    248       Interacts with the 53BP2 SH3 domain.
FT   REGION      256    294       Interaction with E4F1.
FT   REGION      273    280       Interaction with DNA.
FT   REGION      300    393       Interaction with CARM1.
FT   REGION      319    360       Interaction with HIPK2.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF        17     25       TADI.
FT   MOTIF        48     56       TADII.
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT   MOTIF       339    350       Nuclear export signal.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc.
FT   METAL       179    179       Zinc.
FT   METAL       238    238       Zinc.
FT   METAL       242    242       Zinc.
FT   SITE        120    120       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A.
FT   MOD_RES     183    183       Phosphoserine; by AURKB.
FT   MOD_RES     269    269       Phosphoserine; by AURKB.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT   MOD_RES     305    305       N6-acetyllysine.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT   MOD_RES     381    381       N6-acetyllysine.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT   MOD_RES     382    382       N6-methyllysine; by SETD8; alternate.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   VAR_SEQ       1    132       Missing (in isoform 7, isoform 8 and
FT                                isoform 9).
FT                                /FTId=VSP_040833.
FT   VAR_SEQ       1     39       Missing (in isoform 4, isoform 5 and
FT                                isoform 6).
FT                                /FTId=VSP_040832.
FT   VAR_SEQ     332    346       IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in
FT                                isoform 3, isoform 6 and isoform 9).
FT                                /FTId=VSP_040560.
FT   VAR_SEQ     332    341       IRGRERFEMF -> DQTSFQKENC (in isoform 2,
FT                                isoform 5 and isoform 8).
FT                                /FTId=VSP_006535.
FT   VAR_SEQ     342    393       Missing (in isoform 2, isoform 5 and
FT                                isoform 8).
FT                                /FTId=VSP_006536.
FT   VAR_SEQ     347    393       Missing (in isoform 3, isoform 6 and
FT                                isoform 9).
FT                                /FTId=VSP_040561.
FT   VARIANT       5      5       Q -> H (in a sporadic cancer; somatic
FT                                mutation; abolishes strongly
FT                                phosphorylation).
FT                                /FTId=VAR_044543.
FT   VARIANT       6      6       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044544.
FT   VARIANT       7      7       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005851.
FT   VARIANT       8      8       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044545.
FT   VARIANT      10     10       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044546.
FT   VARIANT      11     11       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044547.
FT   VARIANT      11     11       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044548.
FT   VARIANT      15     15       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044549.
FT   VARIANT      16     16       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044550.
FT   VARIANT      17     17       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044551.
FT   VARIANT      24     24       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044552.
FT   VARIANT      28     28       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044553.
FT   VARIANT      29     30       NN -> KD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047158.
FT   VARIANT      31     31       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044554.
FT   VARIANT      33     33       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044555.
FT   VARIANT      34     34       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044556.
FT   VARIANT      35     35       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005852.
FT   VARIANT      36     36       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044557.
FT   VARIANT      37     37       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044558.
FT   VARIANT      37     37       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044559.
FT   VARIANT      39     39       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044560.
FT   VARIANT      39     39       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044561.
FT   VARIANT      42     42       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044562.
FT   VARIANT      43     43       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005853.
FT   VARIANT      44     44       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044563.
FT   VARIANT      44     44       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044564.
FT   VARIANT      44     44       M -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044565.
FT   VARIANT      45     45       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044566.
FT   VARIANT      46     46       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044567.
FT   VARIANT      46     46       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044568.
FT   VARIANT      47     47       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044569.
FT   VARIANT      47     47       P -> S (in dbSNP:rs1800371).
FT                                /FTId=VAR_014632.
FT   VARIANT      48     48       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044570.
FT   VARIANT      49     49       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044571.
FT   VARIANT      49     49       D -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044572.
FT   VARIANT      49     49       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044573.
FT   VARIANT      52     52       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044574.
FT   VARIANT      53     53       W -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005854.
FT   VARIANT      53     53       W -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044575.
FT   VARIANT      54     54       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044576.
FT   VARIANT      54     54       F -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044577.
FT   VARIANT      56     56       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044578.
FT   VARIANT      56     56       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044579.
FT   VARIANT      58     58       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044580.
FT   VARIANT      58     58       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044581.
FT   VARIANT      59     59       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044582.
FT   VARIANT      59     59       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044583.
FT   VARIANT      59     59       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045783.
FT   VARIANT      60     60       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044584.
FT   VARIANT      60     60       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044585.
FT   VARIANT      60     60       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005855.
FT   VARIANT      61     61       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044586.
FT   VARIANT      61     61       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044587.
FT   VARIANT      62     62       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044588.
FT   VARIANT      63     63       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044589.
FT   VARIANT      63     63       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044590.
FT   VARIANT      65     65       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044591.
FT   VARIANT      66     66       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044592.
FT   VARIANT      66     66       M -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044593.
FT   VARIANT      67     67       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044594.
FT   VARIANT      67     67       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044595.
FT   VARIANT      67     67       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044596.
FT   VARIANT      68     68       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044597.
FT   VARIANT      68     68       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044598.
FT   VARIANT      69     69       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044599.
FT   VARIANT      69     69       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044600.
FT   VARIANT      69     69       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044601.
FT   VARIANT      69     69       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044602.
FT   VARIANT      70     70       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044603.
FT   VARIANT      71     71       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044604.
FT   VARIANT      72     72       P -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045784.
FT   VARIANT      72     72       P -> G (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045785.
FT   VARIANT      72     72       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045786.
FT   VARIANT      72     72       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045787.
FT   VARIANT      72     72       P -> R (in dbSNP:rs1042522).
FT                                /FTId=VAR_005856.
FT   VARIANT      73     73       V -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044605.
FT   VARIANT      73     73       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044606.
FT   VARIANT      73     73       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044607.
FT   VARIANT      74     74       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044608.
FT   VARIANT      75     75       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044609.
FT   VARIANT      75     75       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044610.
FT   VARIANT      75     75       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044611.
FT   VARIANT      76     76       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044612.
FT   VARIANT      76     76       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044613.
FT   VARIANT      77     77       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044614.
FT   VARIANT      78     78       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044615.
FT   VARIANT      79     79       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044616.
FT   VARIANT      79     79       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005857.
FT   VARIANT      79     79       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044617.
FT   VARIANT      80     80       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044618.
FT   VARIANT      80     80       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044619.
FT   VARIANT      81     81       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044620.
FT   VARIANT      82     82       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044621.
FT   VARIANT      82     82       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044622.
FT   VARIANT      83     83       A -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044623.
FT   VARIANT      83     83       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044624.
FT   VARIANT      84     84       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044625.
FT   VARIANT      84     84       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044626.
FT   VARIANT      85     85       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044627.
FT   VARIANT      85     85       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044628.
FT   VARIANT      86     86       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044629.
FT   VARIANT      87     87       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005858.
FT   VARIANT      88     88       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044630.
FT   VARIANT      88     88       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044631.
FT   VARIANT      89     89       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044632.
FT   VARIANT      89     89       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044633.
FT   VARIANT      90     90       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044634.
FT   VARIANT      90     90       S -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044635.
FT   VARIANT      91     91       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044636.
FT   VARIANT      92     92       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044637.
FT   VARIANT      92     92       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044638.
FT   VARIANT      92     92       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044639.
FT   VARIANT      93     93       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044640.
FT   VARIANT      93     93       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044641.
FT   VARIANT      94     94       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044642.
FT   VARIANT      94     94       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005859.
FT   VARIANT      95     95       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044643.
FT   VARIANT      95     95       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044644.
FT   VARIANT      96     96       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044645.
FT   VARIANT      96     96       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044646.
FT   VARIANT      96     96       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044647.
FT   VARIANT      97     97       V -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044648.
FT   VARIANT      97     97       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044649.
FT   VARIANT      97     97       V -> I (in familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_044650.
FT   VARIANT      98     98       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044651.
FT   VARIANT      98     98       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044652.
FT   VARIANT      99     99       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044653.
FT   VARIANT      99     99       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044654.
FT   VARIANT     100    100       Q -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044655.
FT   VARIANT     101    101       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044656.
FT   VARIANT     101    101       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044657.
FT   VARIANT     102    102       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044658.
FT   VARIANT     104    104       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044659.
FT   VARIANT     104    104       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044660.
FT   VARIANT     105    105       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044661.
FT   VARIANT     105    105       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044662.
FT   VARIANT     105    105       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044663.
FT   VARIANT     105    105       G -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044664.
FT   VARIANT     105    105       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044665.
FT   VARIANT     106    106       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044666.
FT   VARIANT     106    106       S -> R (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044667.
FT   VARIANT     107    107       Y -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044668.
FT   VARIANT     107    107       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044669.
FT   VARIANT     107    107       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044670.
FT   VARIANT     108    108       G -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044671.
FT   VARIANT     108    108       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044672.
FT   VARIANT     109    109       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044673.
FT   VARIANT     109    109       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044674.
FT   VARIANT     109    109       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044675.
FT   VARIANT     110    110       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005860.
FT   VARIANT     110    110       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044676.
FT   VARIANT     110    110       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044677.
FT   VARIANT     110    110       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation; does not
FT                                induce SNAI1 degradation).
FT                                /FTId=VAR_005861.
FT   VARIANT     110    110       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                /FTId=VAR_005862.
FT   VARIANT     110    110       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044678.
FT   VARIANT     111    111       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044679.
FT   VARIANT     111    111       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044680.
FT   VARIANT     111    111       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044681.
FT   VARIANT     111    111       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044682.
FT   VARIANT     112    112       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044683.
FT   VARIANT     112    112       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044684.
FT   VARIANT     113    113       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005863.
FT   VARIANT     113    113       F -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045788.
FT   VARIANT     113    113       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044685.
FT   VARIANT     113    113       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044686.
FT   VARIANT     113    113       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044687.
FT   VARIANT     113    113       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033033.
FT   VARIANT     115    115       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044688.
FT   VARIANT     116    116       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044689.
FT   VARIANT     116    116       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044690.
FT   VARIANT     116    116       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044691.
FT   VARIANT     117    117       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044692.
FT   VARIANT     117    117       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044693.
FT   VARIANT     118    118       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044694.
FT   VARIANT     118    118       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044695.
FT   VARIANT     118    118       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044696.
FT   VARIANT     119    119       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044697.
FT   VARIANT     119    119       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044698.
FT   VARIANT     120    120       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044699.
FT   VARIANT     120    120       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044700.
FT   VARIANT     120    120       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044701.
FT   VARIANT     120    120       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044702.
FT   VARIANT     121    121       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044703.
FT   VARIANT     122    122       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044704.
FT   VARIANT     123    123       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044705.
FT   VARIANT     123    123       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044706.
FT   VARIANT     124    124       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044707.
FT   VARIANT     124    124       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044708.
FT   VARIANT     124    124       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044709.
FT   VARIANT     124    124       C -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044710.
FT   VARIANT     124    124       C -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044711.
FT   VARIANT     125    125       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044712.
FT   VARIANT     125    125       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044713.
FT   VARIANT     125    125       T -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005864.
FT   VARIANT     125    125       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044714.
FT   VARIANT     125    125       T -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044715.
FT   VARIANT     126    126       Y -> C (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044716.
FT   VARIANT     126    126       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005865.
FT   VARIANT     126    126       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044717.
FT   VARIANT     126    126       Y -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045789.
FT   VARIANT     126    126       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044718.
FT   VARIANT     126    126       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005866.
FT   VARIANT     126    126       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044719.
FT   VARIANT     127    127       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044720.
FT   VARIANT     127    127       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005867.
FT   VARIANT     127    127       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044721.
FT   VARIANT     127    127       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044722.
FT   VARIANT     127    127       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044723.
FT   VARIANT     128    128       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044724.
FT   VARIANT     128    128       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044725.
FT   VARIANT     128    128       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044726.
FT   VARIANT     128    128       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005868.
FT   VARIANT     129    129       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005869.
FT   VARIANT     129    129       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044727.
FT   VARIANT     129    129       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044728.
FT   VARIANT     129    129       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044729.
FT   VARIANT     130    130       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044730.
FT   VARIANT     130    130       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044731.
FT   VARIANT     130    130       L -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044732.
FT   VARIANT     130    130       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044733.
FT   VARIANT     130    130       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005870.
FT   VARIANT     130    130       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044734.
FT   VARIANT     131    131       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044735.
FT   VARIANT     131    131       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044736.
FT   VARIANT     131    131       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044737.
FT   VARIANT     131    131       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005872.
FT   VARIANT     131    131       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005871.
FT   VARIANT     131    131       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044738.
FT   VARIANT     131    131       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044739.
FT   VARIANT     132    133       KM -> NL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047159.
FT   VARIANT     132    132       K -> E (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044740.
FT   VARIANT     132    132       K -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045790.
FT   VARIANT     132    132       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005873.
FT   VARIANT     132    132       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044741.
FT   VARIANT     132    132       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005874.
FT   VARIANT     132    132       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044742.
FT   VARIANT     132    132       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044743.
FT   VARIANT     132    132       K -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045791.
FT   VARIANT     133    133       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044744.
FT   VARIANT     133    133       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044745.
FT   VARIANT     133    133       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044746.
FT   VARIANT     133    133       M -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044747.
FT   VARIANT     133    133       M -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934873).
FT                                /FTId=VAR_005875.
FT   VARIANT     133    133       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044748.
FT   VARIANT     134    134       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044749.
FT   VARIANT     134    134       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044750.
FT   VARIANT     134    134       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036504.
FT   VARIANT     134    134       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044751.
FT   VARIANT     134    134       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044752.
FT   VARIANT     135    135       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005877.
FT   VARIANT     135    135       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044753.
FT   VARIANT     135    135       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044754.
FT   VARIANT     135    135       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005876.
FT   VARIANT     135    135       C -> T (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045792.
FT   VARIANT     135    135       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044755.
FT   VARIANT     135    135       C -> Y (in sporadic cancers; somatic
FT                                mutation; decreased E6-mediated binding
FT                                to E6-AP).
FT                                /FTId=VAR_044756.
FT   VARIANT     136    136       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005878.
FT   VARIANT     136    136       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044757.
FT   VARIANT     136    136       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005879.
FT   VARIANT     136    136       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044758.
FT   VARIANT     136    136       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044759.
FT   VARIANT     137    137       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044760.
FT   VARIANT     137    137       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044761.
FT   VARIANT     137    137       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005880.
FT   VARIANT     137    137       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044762.
FT   VARIANT     138    138       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044763.
FT   VARIANT     138    138       A -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934875).
FT                                /FTId=VAR_005881.
FT   VARIANT     138    138       A -> S (in LFS; germline mutation).
FT                                /FTId=VAR_044764.
FT   VARIANT     138    138       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044765.
FT   VARIANT     138    138       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033034.
FT   VARIANT     139    139       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044766.
FT   VARIANT     139    139       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005882.
FT   VARIANT     139    139       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044767.
FT   VARIANT     139    139       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044768.
FT   VARIANT     139    139       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044769.
FT   VARIANT     140    140       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044770.
FT   VARIANT     140    140       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044771.
FT   VARIANT     140    140       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044772.
FT   VARIANT     140    140       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044773.
FT   VARIANT     140    140       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044774.
FT   VARIANT     141    141       C -> A (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045793.
FT   VARIANT     141    141       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005885.
FT   VARIANT     141    141       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005884.
FT   VARIANT     141    141       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044775.
FT   VARIANT     141    141       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044776.
FT   VARIANT     141    141       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044777.
FT   VARIANT     141    141       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005886.
FT   VARIANT     142    142       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044778.
FT   VARIANT     142    142       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045794.
FT   VARIANT     142    142       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044779.
FT   VARIANT     142    142       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044780.
FT   VARIANT     142    142       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044781.
FT   VARIANT     142    142       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044782.
FT   VARIANT     142    142       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044783.
FT   VARIANT     143    143       V -> A (in sporadic cancers; somatic
FT                                mutation; strong DNA binding ability at
FT                                32.5 degrees Celsius; strong reduction of
FT                                transcriptional activity at 37.5 degrees
FT                                Celsius).
FT                                /FTId=VAR_005887.
FT   VARIANT     143    143       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044784.
FT   VARIANT     143    143       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044785.
FT   VARIANT     143    143       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044786.
FT   VARIANT     143    143       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044787.
FT   VARIANT     144    144       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044788.
FT   VARIANT     144    144       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044789.
FT   VARIANT     144    144       Q -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044790.
FT   VARIANT     144    144       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005888.
FT   VARIANT     144    144       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044791.
FT   VARIANT     145    145       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044792.
FT   VARIANT     145    145       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005889.
FT   VARIANT     145    145       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005890.
FT   VARIANT     145    145       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044793.
FT   VARIANT     145    145       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044794.
FT   VARIANT     146    146       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044795.
FT   VARIANT     146    146       W -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044796.
FT   VARIANT     146    146       W -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044797.
FT   VARIANT     146    146       W -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044798.
FT   VARIANT     146    146       W -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044799.
FT   VARIANT     147    147       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044800.
FT   VARIANT     147    147       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005891.
FT   VARIANT     147    147       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044801.
FT   VARIANT     147    147       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044802.
FT   VARIANT     147    147       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005892.
FT   VARIANT     147    147       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044803.
FT   VARIANT     148    148       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044804.
FT   VARIANT     148    148       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044805.
FT   VARIANT     148    148       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044806.
FT   VARIANT     148    148       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044807.
FT   VARIANT     148    148       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044808.
FT   VARIANT     148    148       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044809.
FT   VARIANT     149    149       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044810.
FT   VARIANT     149    149       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005893.
FT   VARIANT     149    149       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044811.
FT   VARIANT     150    150       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044812.
FT   VARIANT     150    150       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044813.
FT   VARIANT     150    150       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044814.
FT   VARIANT     150    150       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044815.
FT   VARIANT     150    150       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044816.
FT   VARIANT     150    150       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044817.
FT   VARIANT     151    151       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005894.
FT   VARIANT     151    151       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044818.
FT   VARIANT     151    151       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044819.
FT   VARIANT     151    151       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044820.
FT   VARIANT     151    151       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                /FTId=VAR_005895.
FT   VARIANT     151    151       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005896.
FT   VARIANT     152    152       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044821.
FT   VARIANT     152    152       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005897.
FT   VARIANT     152    152       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044822.
FT   VARIANT     152    152       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044823.
FT   VARIANT     152    152       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005898.
FT   VARIANT     152    152       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044824.
FT   VARIANT     153    153       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044825.
FT   VARIANT     153    153       P -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045795.
FT   VARIANT     153    153       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044826.
FT   VARIANT     153    153       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044827.
FT   VARIANT     153    153       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044828.
FT   VARIANT     153    153       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044829.
FT   VARIANT     153    153       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005899.
FT   VARIANT     154    154       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044830.
FT   VARIANT     154    154       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044831.
FT   VARIANT     154    154       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044832.
FT   VARIANT     154    154       G -> I (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045796.
FT   VARIANT     154    154       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044833.
FT   VARIANT     154    154       G -> V (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005900.
FT   VARIANT     155    155       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005901.
FT   VARIANT     155    155       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044834.
FT   VARIANT     155    155       T -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044835.
FT   VARIANT     155    155       T -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044836.
FT   VARIANT     155    155       T -> P (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                /FTId=VAR_044837.
FT   VARIANT     155    155       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044838.
FT   VARIANT     156    156       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044839.
FT   VARIANT     156    156       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044840.
FT   VARIANT     156    156       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044841.
FT   VARIANT     156    156       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044842.
FT   VARIANT     156    156       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005902.
FT   VARIANT     156    156       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044843.
FT   VARIANT     157    157       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044844.
FT   VARIANT     157    157       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005903.
FT   VARIANT     157    157       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005904.
FT   VARIANT     157    157       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044845.
FT   VARIANT     157    157       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_012977.
FT   VARIANT     157    157       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044846.
FT   VARIANT     158    158       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005905.
FT   VARIANT     158    158       R -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045797.
FT   VARIANT     158    158       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005906.
FT   VARIANT     158    158       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005907.
FT   VARIANT     158    158       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044847.
FT   VARIANT     158    158       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044848.
FT   VARIANT     158    158       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044849.
FT   VARIANT     158    158       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044850.
FT   VARIANT     158    158       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045798.
FT   VARIANT     159    159       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044851.
FT   VARIANT     159    159       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045799.
FT   VARIANT     159    159       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044852.
FT   VARIANT     159    159       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044853.
FT   VARIANT     159    159       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044854.
FT   VARIANT     159    159       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044855.
FT   VARIANT     159    159       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044856.
FT   VARIANT     160    161       MA -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047160.
FT   VARIANT     160    161       MA -> IS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047161.
FT   VARIANT     160    161       MA -> IT (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047162.
FT   VARIANT     160    160       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005908.
FT   VARIANT     160    160       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044857.
FT   VARIANT     160    160       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044858.
FT   VARIANT     160    160       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044859.
FT   VARIANT     161    161       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044860.
FT   VARIANT     161    161       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045800.
FT   VARIANT     161    161       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044861.
FT   VARIANT     161    161       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044862.
FT   VARIANT     161    161       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005909.
FT   VARIANT     161    161       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044863.
FT   VARIANT     161    161       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044864.
FT   VARIANT     162    162       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044865.
FT   VARIANT     162    162       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044866.
FT   VARIANT     162    162       I -> N (in a breast cancer with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044867.
FT   VARIANT     162    162       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005910.
FT   VARIANT     162    162       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044868.
FT   VARIANT     162    162       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005911.
FT   VARIANT     163    163       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_033035.
FT   VARIANT     163    163       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044869.
FT   VARIANT     163    163       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044870.
FT   VARIANT     163    163       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005912.
FT   VARIANT     163    163       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044871.
FT   VARIANT     163    163       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044872.
FT   VARIANT     164    164       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044873.
FT   VARIANT     164    164       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044874.
FT   VARIANT     164    164       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005913.
FT   VARIANT     164    164       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005914.
FT   VARIANT     164    164       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044875.
FT   VARIANT     164    164       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044876.
FT   VARIANT     165    165       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044877.
FT   VARIANT     165    165       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044878.
FT   VARIANT     165    165       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005915.
FT   VARIANT     165    165       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044879.
FT   VARIANT     165    165       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005916.
FT   VARIANT     166    166       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044880.
FT   VARIANT     166    166       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044881.
FT   VARIANT     166    166       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005917.
FT   VARIANT     166    166       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044882.
FT   VARIANT     166    166       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044883.
FT   VARIANT     167    168       QH -> HD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047163.
FT   VARIANT     167    168       QH -> YL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047164.
FT   VARIANT     167    167       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044884.
FT   VARIANT     167    167       Q -> K (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044885.
FT   VARIANT     167    167       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044886.
FT   VARIANT     167    167       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044887.
FT   VARIANT     168    169       HM -> LI (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047165.
FT   VARIANT     168    168       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044888.
FT   VARIANT     168    168       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044889.
FT   VARIANT     168    168       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044890.
FT   VARIANT     168    168       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044891.
FT   VARIANT     168    168       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044892.
FT   VARIANT     168    168       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005918.
FT   VARIANT     168    168       H -> V (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045801.
FT   VARIANT     168    168       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044893.
FT   VARIANT     169    170       MT -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047166.
FT   VARIANT     169    169       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005919.
FT   VARIANT     169    169       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044894.
FT   VARIANT     169    169       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005920.
FT   VARIANT     169    169       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044895.
FT   VARIANT     170    170       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044896.
FT   VARIANT     170    170       T -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044897.
FT   VARIANT     170    170       T -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005921.
FT   VARIANT     170    170       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044898.
FT   VARIANT     170    170       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005922.
FT   VARIANT     171    171       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044899.
FT   VARIANT     171    171       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044900.
FT   VARIANT     171    171       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044901.
FT   VARIANT     171    171       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044902.
FT   VARIANT     171    171       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044903.
FT   VARIANT     171    171       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044904.
FT   VARIANT     172    172       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005923.
FT   VARIANT     172    172       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044905.
FT   VARIANT     172    172       V -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044906.
FT   VARIANT     172    172       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044907.
FT   VARIANT     172    172       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044908.
FT   VARIANT     173    173       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044909.
FT   VARIANT     173    173       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005924.
FT   VARIANT     173    173       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044910.
FT   VARIANT     173    173       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005925.
FT   VARIANT     173    173       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005926.
FT   VARIANT     173    173       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045802.
FT   VARIANT     174    174       R -> G (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044911.
FT   VARIANT     174    174       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005927.
FT   VARIANT     174    174       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044912.
FT   VARIANT     174    174       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044913.
FT   VARIANT     174    174       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044914.
FT   VARIANT     174    174       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044915.
FT   VARIANT     175    175       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005928.
FT   VARIANT     175    175       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005929.
FT   VARIANT     175    175       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation;
FT                                dbSNP:rs28934578).
FT                                /FTId=VAR_005932.
FT   VARIANT     175    175       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005930.
FT   VARIANT     175    175       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005931.
FT   VARIANT     175    175       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044916.
FT   VARIANT     175    175       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044917.
FT   VARIANT     176    177       CP -> FS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047167.
FT   VARIANT     176    176       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005933.
FT   VARIANT     176    176       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044918.
FT   VARIANT     176    176       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044919.
FT   VARIANT     176    176       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044920.
FT   VARIANT     176    176       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005934.
FT   VARIANT     176    176       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044921.
FT   VARIANT     177    177       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044922.
FT   VARIANT     177    177       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045803.
FT   VARIANT     177    177       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044923.
FT   VARIANT     177    177       P -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045804.
FT   VARIANT     177    177       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005935.
FT   VARIANT     177    177       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036505.
FT   VARIANT     177    177       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044924.
FT   VARIANT     177    177       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044925.
FT   VARIANT     178    179       HH -> QS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047168.
FT   VARIANT     178    178       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044926.
FT   VARIANT     178    178       H -> HPHP (in a Burkitt lymphoma).
FT                                /FTId=VAR_005936.
FT   VARIANT     178    178       H -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044927.
FT   VARIANT     178    178       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044928.
FT   VARIANT     178    178       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044929.
FT   VARIANT     178    178       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044930.
FT   VARIANT     178    178       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044931.
FT   VARIANT     178    178       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044932.
FT   VARIANT     179    179       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044933.
FT   VARIANT     179    179       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044934.
FT   VARIANT     179    179       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044935.
FT   VARIANT     179    179       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044936.
FT   VARIANT     179    179       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044937.
FT   VARIANT     179    179       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044938.
FT   VARIANT     179    179       H -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044939.
FT   VARIANT     180    180       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044940.
FT   VARIANT     180    180       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044941.
FT   VARIANT     180    180       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044942.
FT   VARIANT     180    180       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044943.
FT   VARIANT     180    180       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044944.
FT   VARIANT     180    180       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044945.
FT   VARIANT     181    181       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044946.
FT   VARIANT     181    181       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044947.
FT   VARIANT     181    181       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044948.
FT   VARIANT     181    181       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_005937.
FT   VARIANT     181    181       R -> P (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044949.
FT   VARIANT     181    181       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044950.
FT   VARIANT     182    182       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044951.
FT   VARIANT     182    182       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005938.
FT   VARIANT     182    182       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044952.
FT   VARIANT     183    183       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044953.
FT   VARIANT     183    183       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044954.
FT   VARIANT     184    184       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044955.
FT   VARIANT     184    184       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044956.
FT   VARIANT     184    184       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047169.
FT   VARIANT     184    184       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044957.
FT   VARIANT     184    184       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005939.
FT   VARIANT     185    185       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044958.
FT   VARIANT     185    185       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044959.
FT   VARIANT     185    185       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044960.
FT   VARIANT     185    185       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044961.
FT   VARIANT     185    185       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044962.
FT   VARIANT     185    185       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044963.
FT   VARIANT     186    186       D -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044964.
FT   VARIANT     186    186       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044965.
FT   VARIANT     186    186       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044966.
FT   VARIANT     186    186       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044967.
FT   VARIANT     186    186       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044968.
FT   VARIANT     186    186       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005940.
FT   VARIANT     187    187       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005941.
FT   VARIANT     187    187       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044969.
FT   VARIANT     187    187       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045805.
FT   VARIANT     187    187       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044970.
FT   VARIANT     187    187       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005942.
FT   VARIANT     187    187       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044971.
FT   VARIANT     188    188       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044972.
FT   VARIANT     188    188       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044973.
FT   VARIANT     189    189       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044974.
FT   VARIANT     189    189       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044975.
FT   VARIANT     189    189       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005943.
FT   VARIANT     189    189       A -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044976.
FT   VARIANT     189    189       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044977.
FT   VARIANT     189    189       A -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044978.
FT   VARIANT     190    190       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044979.
FT   VARIANT     190    190       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044980.
FT   VARIANT     190    190       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005944.
FT   VARIANT     190    190       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044981.
FT   VARIANT     190    190       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044982.
FT   VARIANT     190    190       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044983.
FT   VARIANT     191    191       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044984.
FT   VARIANT     191    191       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044985.
FT   VARIANT     191    191       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044986.
FT   VARIANT     191    191       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044987.
FT   VARIANT     191    191       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005945.
FT   VARIANT     192    193       QH -> HN (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047170.
FT   VARIANT     192    193       QH -> HY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047171.
FT   VARIANT     192    192       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044988.
FT   VARIANT     192    192       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044989.
FT   VARIANT     192    192       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044990.
FT   VARIANT     192    192       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044991.
FT   VARIANT     192    192       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005946.
FT   VARIANT     193    193       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005947.
FT   VARIANT     193    193       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044992.
FT   VARIANT     193    193       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044993.
FT   VARIANT     193    193       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044994.
FT   VARIANT     193    193       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044995.
FT   VARIANT     193    193       H -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005948.
FT   VARIANT     193    193       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044996.
FT   VARIANT     194    194       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044997.
FT   VARIANT     194    194       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044998.
FT   VARIANT     194    194       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044999.
FT   VARIANT     194    194       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005949.
FT   VARIANT     194    194       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005950.
FT   VARIANT     194    194       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045000.
FT   VARIANT     195    195       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045001.
FT   VARIANT     195    195       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047172.
FT   VARIANT     195    195       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045002.
FT   VARIANT     195    195       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045003.
FT   VARIANT     195    195       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005951.
FT   VARIANT     195    195       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045004.
FT   VARIANT     195    195       I -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045806.
FT   VARIANT     196    196       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045005.
FT   VARIANT     196    196       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045006.
FT   VARIANT     196    196       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045007.
FT   VARIANT     196    196       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045008.
FT   VARIANT     196    196       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045009.
FT   VARIANT     197    197       V -> E (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045010.
FT   VARIANT     197    197       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045011.
FT   VARIANT     197    197       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045012.
FT   VARIANT     197    197       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045013.
FT   VARIANT     198    198       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045014.
FT   VARIANT     198    198       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045015.
FT   VARIANT     198    198       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005952.
FT   VARIANT     198    198       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045016.
FT   VARIANT     198    198       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045017.
FT   VARIANT     199    199       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045018.
FT   VARIANT     199    199       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045019.
FT   VARIANT     199    199       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045020.
FT   VARIANT     199    199       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045021.
FT   VARIANT     200    200       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045022.
FT   VARIANT     200    200       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045023.
FT   VARIANT     200    200       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045024.
FT   VARIANT     200    200       N -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045807.
FT   VARIANT     200    200       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045025.
FT   VARIANT     200    200       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045026.
FT   VARIANT     201    202       LR -> FC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047173.
FT   VARIANT     201    201       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045027.
FT   VARIANT     201    201       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045028.
FT   VARIANT     201    201       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045029.
FT   VARIANT     202    202       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045030.
FT   VARIANT     202    202       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045031.
FT   VARIANT     202    202       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045032.
FT   VARIANT     202    202       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045033.
FT   VARIANT     202    202       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045034.
FT   VARIANT     202    202       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045035.
FT   VARIANT     203    204       VE -> LV (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047174.
FT   VARIANT     203    203       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045036.
FT   VARIANT     203    203       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045037.
FT   VARIANT     203    203       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045038.
FT   VARIANT     203    203       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045039.
FT   VARIANT     203    203       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045808.
FT   VARIANT     204    204       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045040.
FT   VARIANT     204    204       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045041.
FT   VARIANT     204    204       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045042.
FT   VARIANT     204    204       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045043.
FT   VARIANT     204    204       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045044.
FT   VARIANT     204    204       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045045.
FT   VARIANT     205    205       Y -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005953.
FT   VARIANT     205    205       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005954.
FT   VARIANT     205    205       Y -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047175.
FT   VARIANT     205    205       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045046.
FT   VARIANT     205    205       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045047.
FT   VARIANT     205    205       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045048.
FT   VARIANT     206    206       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045049.
FT   VARIANT     206    206       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045050.
FT   VARIANT     207    208       DD -> EY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047176.
FT   VARIANT     207    207       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045051.
FT   VARIANT     207    207       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045052.
FT   VARIANT     207    207       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045053.
FT   VARIANT     207    207       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045054.
FT   VARIANT     207    207       D -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045055.
FT   VARIANT     207    207       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045056.
FT   VARIANT     208    208       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045057.
FT   VARIANT     208    208       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045058.
FT   VARIANT     208    208       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045059.
FT   VARIANT     208    208       D -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045809.
FT   VARIANT     208    208       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045060.
FT   VARIANT     208    208       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045061.
FT   VARIANT     208    208       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045062.
FT   VARIANT     209    209       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045063.
FT   VARIANT     209    209       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045064.
FT   VARIANT     209    209       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045065.
FT   VARIANT     209    209       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045066.
FT   VARIANT     210    210       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045067.
FT   VARIANT     210    210       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045068.
FT   VARIANT     210    210       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045069.
FT   VARIANT     210    210       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045070.
FT   VARIANT     210    210       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045071.
FT   VARIANT     210    210       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045072.
FT   VARIANT     210    210       N -> Y (in a familial cancer not matching
FT                                LFS; germline mutation).
FT                                /FTId=VAR_045073.
FT   VARIANT     211    211       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045074.
FT   VARIANT     211    211       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045075.
FT   VARIANT     211    211       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045076.
FT   VARIANT     211    211       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045077.
FT   VARIANT     211    211       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045078.
FT   VARIANT     212    212       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045079.
FT   VARIANT     212    212       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045080.
FT   VARIANT     212    212       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045081.
FT   VARIANT     212    212       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045082.
FT   VARIANT     212    212       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045083.
FT   VARIANT     213    213       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045084.
FT   VARIANT     213    213       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045085.
FT   VARIANT     213    213       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_036506.
FT   VARIANT     213    213       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005955.
FT   VARIANT     213    213       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045086.
FT   VARIANT     214    214       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045087.
FT   VARIANT     214    214       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045088.
FT   VARIANT     214    214       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047177.
FT   VARIANT     214    214       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045089.
FT   VARIANT     214    214       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045090.
FT   VARIANT     215    215       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045091.
FT   VARIANT     215    215       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045092.
FT   VARIANT     215    215       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045093.
FT   VARIANT     215    215       S -> K (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045810.
FT   VARIANT     215    215       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045094.
FT   VARIANT     215    215       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045095.
FT   VARIANT     215    215       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045096.
FT   VARIANT     216    216       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045097.
FT   VARIANT     216    216       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045098.
FT   VARIANT     216    216       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045099.
FT   VARIANT     216    216       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045100.
FT   VARIANT     216    216       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005956.
FT   VARIANT     216    216       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045811.
FT   VARIANT     217    217       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045101.
FT   VARIANT     217    217       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045102.
FT   VARIANT     217    217       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045103.
FT   VARIANT     217    217       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045104.
FT   VARIANT     217    217       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045105.
FT   VARIANT     217    217       V -> M (in dbSNP:rs35163653).
FT                                /FTId=VAR_047178.
FT   VARIANT     218    218       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045106.
FT   VARIANT     218    218       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045107.
FT   VARIANT     218    218       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045108.
FT   VARIANT     218    218       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045109.
FT   VARIANT     218    218       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045110.
FT   VARIANT     219    219       P -> C (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045812.
FT   VARIANT     219    219       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045111.
FT   VARIANT     219    219       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045112.
FT   VARIANT     219    219       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045113.
FT   VARIANT     219    219       P -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045114.
FT   VARIANT     219    219       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045115.
FT   VARIANT     220    220       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005957.
FT   VARIANT     220    220       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045116.
FT   VARIANT     220    220       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045117.
FT   VARIANT     220    220       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005958.
FT   VARIANT     220    220       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045118.
FT   VARIANT     220    220       Y -> S (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005959.
FT   VARIANT     221    221       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045119.
FT   VARIANT     221    221       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045120.
FT   VARIANT     221    221       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045121.
FT   VARIANT     221    221       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045122.
FT   VARIANT     221    221       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045123.
FT   VARIANT     222    222       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045124.
FT   VARIANT     222    222       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045125.
FT   VARIANT     222    222       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045126.
FT   VARIANT     222    222       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045127.
FT   VARIANT     222    222       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045128.
FT   VARIANT     222    222       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045129.
FT   VARIANT     223    223       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047179.
FT   VARIANT     223    223       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045130.
FT   VARIANT     223    223       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045131.
FT   VARIANT     223    223       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045132.
FT   VARIANT     223    223       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045133.
FT   VARIANT     223    223       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045134.
FT   VARIANT     224    224       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045135.
FT   VARIANT     224    224       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045136.
FT   VARIANT     224    224       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045137.
FT   VARIANT     224    224       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045138.
FT   VARIANT     225    225       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045139.
FT   VARIANT     225    225       V -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045140.
FT   VARIANT     225    225       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045141.
FT   VARIANT     225    225       V -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045142.
FT   VARIANT     225    225       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045143.
FT   VARIANT     225    225       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045144.
FT   VARIANT     226    226       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045145.
FT   VARIANT     226    226       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047180.
FT   VARIANT     226    226       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045844.
FT   VARIANT     226    226       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045146.
FT   VARIANT     226    226       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045147.
FT   VARIANT     227    227       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045148.
FT   VARIANT     227    227       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045149.
FT   VARIANT     227    227       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045150.
FT   VARIANT     227    227       S -> T (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045151.
FT   VARIANT     228    228       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045152.
FT   VARIANT     228    228       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005960.
FT   VARIANT     228    228       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045153.
FT   VARIANT     228    228       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045154.
FT   VARIANT     228    228       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045155.
FT   VARIANT     228    228       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045845.
FT   VARIANT     228    228       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045156.
FT   VARIANT     228    228       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045157.
FT   VARIANT     229    229       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045158.
FT   VARIANT     229    229       C -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045846.
FT   VARIANT     229    229       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045159.
FT   VARIANT     229    229       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045160.
FT   VARIANT     229    229       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045161.
FT   VARIANT     230    230       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045162.
FT   VARIANT     230    230       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005961.
FT   VARIANT     230    230       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045163.
FT   VARIANT     230    230       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045164.
FT   VARIANT     230    230       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045165.
FT   VARIANT     231    231       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045166.
FT   VARIANT     231    231       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045167.
FT   VARIANT     231    231       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045168.
FT   VARIANT     231    231       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045169.
FT   VARIANT     232    232       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045170.
FT   VARIANT     232    232       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045171.
FT   VARIANT     232    232       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045172.
FT   VARIANT     232    232       I -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                /FTId=VAR_045173.
FT   VARIANT     232    232       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005962.
FT   VARIANT     232    232       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045174.
FT   VARIANT     233    233       H -> D (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045175.
FT   VARIANT     233    233       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045176.
FT   VARIANT     233    233       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045177.
FT   VARIANT     233    233       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045178.
FT   VARIANT     233    233       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047181.
FT   VARIANT     233    233       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045179.
FT   VARIANT     234    234       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005963.
FT   VARIANT     234    234       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045180.
FT   VARIANT     234    234       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045181.
FT   VARIANT     234    234       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005964.
FT   VARIANT     234    234       Y -> K (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045847.
FT   VARIANT     234    234       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045182.
FT   VARIANT     234    234       Y -> Q (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045848.
FT   VARIANT     234    234       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045183.
FT   VARIANT     235    235       N -> D (in an adrenocortical carcinoma
FT                                with no family history; germline mutation
FT                                and in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047182.
FT   VARIANT     235    235       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045184.
FT   VARIANT     235    235       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045185.
FT   VARIANT     235    235       N -> M (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045849.
FT   VARIANT     235    235       N -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045186.
FT   VARIANT     235    235       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045187.
FT   VARIANT     235    235       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045188.
FT   VARIANT     236    236       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045189.
FT   VARIANT     236    236       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045190.
FT   VARIANT     236    236       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045191.
FT   VARIANT     236    236       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045192.
FT   VARIANT     236    236       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045193.
FT   VARIANT     236    236       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045194.
FT   VARIANT     237    237       M -> I (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005965.
FT   VARIANT     237    237       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045195.
FT   VARIANT     237    237       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045196.
FT   VARIANT     237    237       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045197.
FT   VARIANT     237    237       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045198.
FT   VARIANT     237    237       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045199.
FT   VARIANT     238    238       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005966.
FT   VARIANT     238    238       C -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045200.
FT   VARIANT     238    238       C -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045850.
FT   VARIANT     238    238       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045201.
FT   VARIANT     238    238       C -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045202.
FT   VARIANT     238    238       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045203.
FT   VARIANT     238    238       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_005967.
FT   VARIANT     239    239       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045204.
FT   VARIANT     239    239       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045205.
FT   VARIANT     239    239       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045206.
FT   VARIANT     239    239       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045207.
FT   VARIANT     239    239       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045208.
FT   VARIANT     239    239       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045209.
FT   VARIANT     239    239       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045210.
FT   VARIANT     240    240       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045211.
FT   VARIANT     240    240       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045212.
FT   VARIANT     240    240       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005968.
FT   VARIANT     240    240       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045213.
FT   VARIANT     240    240       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045214.
FT   VARIANT     240    240       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045215.
FT   VARIANT     240    240       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045216.
FT   VARIANT     241    241       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033036.
FT   VARIANT     241    241       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045217.
FT   VARIANT     241    241       S -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934573).
FT                                /FTId=VAR_005969.
FT   VARIANT     241    241       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045218.
FT   VARIANT     241    241       S -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047183.
FT   VARIANT     241    241       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045219.
FT   VARIANT     242    242       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005970.
FT   VARIANT     242    242       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045220.
FT   VARIANT     242    242       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045221.
FT   VARIANT     242    242       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045222.
FT   VARIANT     242    242       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045223.
FT   VARIANT     242    242       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045224.
FT   VARIANT     243    244       MG -> IC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047184.
FT   VARIANT     243    244       MG -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047185.
FT   VARIANT     243    243       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045225.
FT   VARIANT     243    243       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045226.
FT   VARIANT     243    243       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045227.
FT   VARIANT     243    243       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045228.
FT   VARIANT     243    243       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045229.
FT   VARIANT     243    243       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045230.
FT   VARIANT     244    244       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047186.
FT   VARIANT     244    244       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045231.
FT   VARIANT     244    244       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934572).
FT                                /FTId=VAR_045232.
FT   VARIANT     244    244       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045233.
FT   VARIANT     244    244       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045234.
FT   VARIANT     244    244       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045235.
FT   VARIANT     244    244       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045236.
FT   VARIANT     245    245       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005971.
FT   VARIANT     245    245       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005972.
FT   VARIANT     245    245       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005973.
FT   VARIANT     245    245       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045237.
FT   VARIANT     245    245       G -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045851.
FT   VARIANT     245    245       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045852.
FT   VARIANT     245    245       G -> L (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045853.
FT   VARIANT     245    245       G -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045854.
FT   VARIANT     245    245       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045238.
FT   VARIANT     245    245       G -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                /FTId=VAR_005974.
FT   VARIANT     245    245       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005975.
FT   VARIANT     246    246       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045239.
FT   VARIANT     246    246       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045240.
FT   VARIANT     246    246       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044020.
FT   VARIANT     246    246       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005976.
FT   VARIANT     246    246       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005977.
FT   VARIANT     246    246       M -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005978.
FT   VARIANT     247    248       NR -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047187.
FT   VARIANT     247    248       NR -> KW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047188.
FT   VARIANT     247    247       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045241.
FT   VARIANT     247    247       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045855.
FT   VARIANT     247    247       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005980.
FT   VARIANT     247    247       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045242.
FT   VARIANT     247    247       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045243.
FT   VARIANT     247    247       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047189.
FT   VARIANT     247    247       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045244.
FT   VARIANT     248    248       R -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045245.
FT   VARIANT     248    248       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005981.
FT   VARIANT     248    248       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005982.
FT   VARIANT     248    248       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045246.
FT   VARIANT     248    248       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs11540652).
FT                                /FTId=VAR_005983.
FT   VARIANT     248    248       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005984.
FT   VARIANT     249    250       RP -> SA (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047190.
FT   VARIANT     249    250       RP -> SS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047191.
FT   VARIANT     249    249       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005985.
FT   VARIANT     249    249       R -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045247.
FT   VARIANT     249    249       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045248.
FT   VARIANT     249    249       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033037.
FT   VARIANT     249    249       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045856.
FT   VARIANT     249    249       R -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation; dbSNP:rs28934571).
FT                                /FTId=VAR_005986.
FT   VARIANT     249    249       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045249.
FT   VARIANT     249    249       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045250.
FT   VARIANT     250    250       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045251.
FT   VARIANT     250    250       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045857.
FT   VARIANT     250    250       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045252.
FT   VARIANT     250    250       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047192.
FT   VARIANT     250    250       P -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045858.
FT   VARIANT     250    250       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045253.
FT   VARIANT     250    250       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045254.
FT   VARIANT     250    250       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045255.
FT   VARIANT     251    251       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045256.
FT   VARIANT     251    251       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045257.
FT   VARIANT     251    251       I -> M (in LFS; germline mutation).
FT                                /FTId=VAR_045258.
FT   VARIANT     251    251       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005987.
FT   VARIANT     251    251       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033038.
FT   VARIANT     251    251       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045259.
FT   VARIANT     251    251       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045260.
FT   VARIANT     252    252       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045261.
FT   VARIANT     252    252       L -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045262.
FT   VARIANT     252    252       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045263.
FT   VARIANT     252    252       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005988.
FT   VARIANT     252    252       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045264.
FT   VARIANT     253    253       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045265.
FT   VARIANT     253    253       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045266.
FT   VARIANT     253    253       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045267.
FT   VARIANT     253    253       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047193.
FT   VARIANT     253    253       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045268.
FT   VARIANT     254    254       I -> D (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045859.
FT   VARIANT     254    254       I -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045269.
FT   VARIANT     254    254       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045270.
FT   VARIANT     254    254       I -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045271.
FT   VARIANT     254    254       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017908.
FT   VARIANT     254    254       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045272.
FT   VARIANT     254    254       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017909.
FT   VARIANT     254    254       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045273.
FT   VARIANT     255    255       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045274.
FT   VARIANT     255    255       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045275.
FT   VARIANT     255    255       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045276.
FT   VARIANT     255    255       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045277.
FT   VARIANT     255    255       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045278.
FT   VARIANT     255    255       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045279.
FT   VARIANT     256    256       T -> I (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045280.
FT   VARIANT     256    256       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045281.
FT   VARIANT     256    256       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045282.
FT   VARIANT     256    256       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045283.
FT   VARIANT     257    257       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005989.
FT   VARIANT     257    257       L -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934577).
FT                                /FTId=VAR_045284.
FT   VARIANT     257    257       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045285.
FT   VARIANT     257    257       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045286.
FT   VARIANT     258    258       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045287.
FT   VARIANT     258    258       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005990.
FT   VARIANT     258    258       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045288.
FT   VARIANT     258    258       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005991.
FT   VARIANT     258    258       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045860.
FT   VARIANT     258    258       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045289.
FT   VARIANT     258    258       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045290.
FT   VARIANT     259    259       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047194.
FT   VARIANT     259    259       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045291.
FT   VARIANT     259    259       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045292.
FT   VARIANT     259    259       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045293.
FT   VARIANT     259    259       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045294.
FT   VARIANT     259    259       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045861.
FT   VARIANT     259    259       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045862.
FT   VARIANT     259    259       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045295.
FT   VARIANT     259    259       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_033039.
FT   VARIANT     260    260       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045296.
FT   VARIANT     260    260       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045297.
FT   VARIANT     260    260       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045298.
FT   VARIANT     260    260       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045299.
FT   VARIANT     260    260       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045300.
FT   VARIANT     260    260       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045301.
FT   VARIANT     261    261       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045302.
FT   VARIANT     261    261       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045303.
FT   VARIANT     261    261       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045304.
FT   VARIANT     261    261       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045305.
FT   VARIANT     261    261       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045306.
FT   VARIANT     262    263       GN -> PD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047195.
FT   VARIANT     262    262       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045307.
FT   VARIANT     262    262       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047196.
FT   VARIANT     262    262       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045863.
FT   VARIANT     262    262       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045308.
FT   VARIANT     262    262       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045309.
FT   VARIANT     263    263       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045310.
FT   VARIANT     263    263       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045311.
FT   VARIANT     263    263       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045312.
FT   VARIANT     263    263       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045313.
FT   VARIANT     263    263       N -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045314.
FT   VARIANT     264    264       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045315.
FT   VARIANT     264    264       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045316.
FT   VARIANT     264    264       L -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045317.
FT   VARIANT     264    264       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045318.
FT   VARIANT     264    264       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045319.
FT   VARIANT     265    265       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045320.
FT   VARIANT     265    265       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045321.
FT   VARIANT     265    265       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045322.
FT   VARIANT     265    265       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047197.
FT   VARIANT     266    266       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045323.
FT   VARIANT     266    266       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045324.
FT   VARIANT     266    266       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045325.
FT   VARIANT     266    266       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045326.
FT   VARIANT     267    267       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045327.
FT   VARIANT     267    267       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045328.
FT   VARIANT     267    267       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045329.
FT   VARIANT     267    267       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045330.
FT   VARIANT     267    267       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs55832599).
FT                                /FTId=VAR_036507.
FT   VARIANT     268    268       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045864.
FT   VARIANT     268    268       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045331.
FT   VARIANT     268    268       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045332.
FT   VARIANT     268    268       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045333.
FT   VARIANT     268    268       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045334.
FT   VARIANT     268    268       N -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045335.
FT   VARIANT     269    269       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045336.
FT   VARIANT     269    269       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045337.
FT   VARIANT     269    269       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047198.
FT   VARIANT     269    269       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045338.
FT   VARIANT     269    269       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045339.
FT   VARIANT     269    269       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045340.
FT   VARIANT     270    270       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045341.
FT   VARIANT     270    270       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045342.
FT   VARIANT     270    270       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045343.
FT   VARIANT     270    270       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045344.
FT   VARIANT     270    270       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045345.
FT   VARIANT     270    270       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045346.
FT   VARIANT     271    271       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045347.
FT   VARIANT     271    271       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045348.
FT   VARIANT     271    271       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045349.
FT   VARIANT     271    271       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_036508.
FT   VARIANT     271    271       E -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045865.
FT   VARIANT     271    271       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045350.
FT   VARIANT     271    271       E -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045866.
FT   VARIANT     271    271       E -> V (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047199.
FT   VARIANT     272    272       V -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045351.
FT   VARIANT     272    272       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045352.
FT   VARIANT     272    272       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045353.
FT   VARIANT     272    272       V -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005992.
FT   VARIANT     272    272       V -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045354.
FT   VARIANT     273    273       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005993.
FT   VARIANT     273    273       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005994.
FT   VARIANT     273    273       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                abolishes sequence-specific DNA binding;
FT                                does not induce SNAI1 degradation;
FT                                dbSNP:rs28934576).
FT                                /FTId=VAR_005995.
FT   VARIANT     273    273       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_036509.
FT   VARIANT     273    273       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045867.
FT   VARIANT     273    273       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045355.
FT   VARIANT     273    273       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045356.
FT   VARIANT     273    273       R -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045357.
FT   VARIANT     273    273       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045868.
FT   VARIANT     274    274       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045358.
FT   VARIANT     274    274       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045359.
FT   VARIANT     274    274       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005997.
FT   VARIANT     274    274       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047200.
FT   VARIANT     274    274       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045360.
FT   VARIANT     274    274       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045361.
FT   VARIANT     275    275       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045362.
FT   VARIANT     275    275       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045363.
FT   VARIANT     275    275       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045364.
FT   VARIANT     275    275       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045365.
FT   VARIANT     275    275       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005999.
FT   VARIANT     275    275       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005998.
FT   VARIANT     276    276       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045366.
FT   VARIANT     276    276       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045367.
FT   VARIANT     276    276       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045368.
FT   VARIANT     276    276       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045369.
FT   VARIANT     276    276       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045370.
FT   VARIANT     276    276       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045371.
FT   VARIANT     277    277       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045372.
FT   VARIANT     277    277       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006000.
FT   VARIANT     277    277       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045373.
FT   VARIANT     277    277       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045374.
FT   VARIANT     277    277       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047201.
FT   VARIANT     277    277       C -> Y (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045375.
FT   VARIANT     278    278       P -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs17849781).
FT                                /FTId=VAR_006001.
FT   VARIANT     278    278       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045869.
FT   VARIANT     278    278       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006002.
FT   VARIANT     278    278       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006003.
FT   VARIANT     278    278       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045376.
FT   VARIANT     278    278       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006004.
FT   VARIANT     278    278       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006005.
FT   VARIANT     279    279       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006006.
FT   VARIANT     279    279       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045377.
FT   VARIANT     279    279       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045378.
FT   VARIANT     279    279       G -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045379.
FT   VARIANT     280    280       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045380.
FT   VARIANT     280    280       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006008.
FT   VARIANT     280    280       R -> K (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_006007.
FT   VARIANT     280    280       R -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045381.
FT   VARIANT     280    280       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045382.
FT   VARIANT     280    280       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006009.
FT   VARIANT     281    282       DR -> EW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047203.
FT   VARIANT     281    281       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006010.
FT   VARIANT     281    281       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006011.
FT   VARIANT     281    281       D -> G (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006012.
FT   VARIANT     281    281       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006013.
FT   VARIANT     281    281       D -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047202.
FT   VARIANT     281    281       D -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045870.
FT   VARIANT     281    281       D -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_006014.
FT   VARIANT     281    281       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045383.
FT   VARIANT     282    282       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045384.
FT   VARIANT     282    282       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045385.
FT   VARIANT     282    282       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006015.
FT   VARIANT     282    282       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045386.
FT   VARIANT     282    282       R -> Q (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045387.
FT   VARIANT     282    282       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation;
FT                                dbSNP:rs28934574).
FT                                /FTId=VAR_006016.
FT   VARIANT     283    283       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006017.
FT   VARIANT     283    283       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006018.
FT   VARIANT     283    283       R -> H (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006019.
FT   VARIANT     283    283       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045388.
FT   VARIANT     283    283       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006020.
FT   VARIANT     283    283       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045389.
FT   VARIANT     284    284       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006021.
FT   VARIANT     284    284       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045390.
FT   VARIANT     284    284       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045391.
FT   VARIANT     284    284       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006022.
FT   VARIANT     285    285       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045392.
FT   VARIANT     285    285       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045393.
FT   VARIANT     285    285       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045394.
FT   VARIANT     285    285       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006023.
FT   VARIANT     285    285       E -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006024.
FT   VARIANT     285    285       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006025.
FT   VARIANT     286    286       E -> A (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006026.
FT   VARIANT     286    286       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006027.
FT   VARIANT     286    286       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006028.
FT   VARIANT     286    286       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006029.
FT   VARIANT     286    286       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045871.
FT   VARIANT     286    286       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006030.
FT   VARIANT     286    286       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045395.
FT   VARIANT     287    287       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047204.
FT   VARIANT     287    287       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045396.
FT   VARIANT     287    287       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045397.
FT   VARIANT     287    287       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045398.
FT   VARIANT     287    287       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045399.
FT   VARIANT     288    288       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045400.
FT   VARIANT     288    288       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045401.
FT   VARIANT     288    288       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045402.
FT   VARIANT     288    288       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045403.
FT   VARIANT     288    288       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045404.
FT   VARIANT     289    289       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045405.
FT   VARIANT     289    289       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045406.
FT   VARIANT     289    289       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045407.
FT   VARIANT     289    289       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045408.
FT   VARIANT     289    289       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045409.
FT   VARIANT     290    290       R -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045410.
FT   VARIANT     290    290       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs55819519).
FT                                /FTId=VAR_045411.
FT   VARIANT     290    290       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045412.
FT   VARIANT     291    291       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045413.
FT   VARIANT     291    291       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045414.
FT   VARIANT     291    291       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045415.
FT   VARIANT     291    291       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047205.
FT   VARIANT     291    291       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045416.
FT   VARIANT     291    291       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045417.
FT   VARIANT     292    292       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045418.
FT   VARIANT     292    292       K -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045872.
FT   VARIANT     292    292       K -> I (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_015819.
FT   VARIANT     292    292       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045419.
FT   VARIANT     292    292       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045420.
FT   VARIANT     292    292       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045421.
FT   VARIANT     292    292       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045422.
FT   VARIANT     293    293       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045423.
FT   VARIANT     293    293       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045424.
FT   VARIANT     293    293       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045425.
FT   VARIANT     293    293       G -> W (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045426.
FT   VARIANT     294    294       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045427.
FT   VARIANT     294    294       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045428.
FT   VARIANT     294    294       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045429.
FT   VARIANT     294    294       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047206.
FT   VARIANT     294    294       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045430.
FT   VARIANT     294    294       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045431.
FT   VARIANT     295    295       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045432.
FT   VARIANT     295    295       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045433.
FT   VARIANT     295    295       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045434.
FT   VARIANT     295    295       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045435.
FT   VARIANT     296    296       H -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045873.
FT   VARIANT     296    296       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045436.
FT   VARIANT     296    296       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047207.
FT   VARIANT     296    296       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045437.
FT   VARIANT     296    296       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006031.
FT   VARIANT     296    296       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045438.
FT   VARIANT     296    296       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045439.
FT   VARIANT     296    296       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045440.
FT   VARIANT     297    297       H -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045441.
FT   VARIANT     297    297       H -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045442.
FT   VARIANT     297    297       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045443.
FT   VARIANT     297    297       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045444.
FT   VARIANT     297    297       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045445.
FT   VARIANT     298    298       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045446.
FT   VARIANT     298    298       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045447.
FT   VARIANT     298    298       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045448.
FT   VARIANT     298    298       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045449.
FT   VARIANT     298    298       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045450.
FT   VARIANT     299    299       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045451.
FT   VARIANT     299    299       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045452.
FT   VARIANT     299    299       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045453.
FT   VARIANT     299    299       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045454.
FT   VARIANT     300    300       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045455.
FT   VARIANT     300    300       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045456.
FT   VARIANT     300    300       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006032.
FT   VARIANT     300    300       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045457.
FT   VARIANT     301    301       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045458.
FT   VARIANT     301    301       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006033.
FT   VARIANT     301    301       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045459.
FT   VARIANT     301    301       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045460.
FT   VARIANT     301    301       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047208.
FT   VARIANT     302    302       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045461.
FT   VARIANT     302    302       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006034.
FT   VARIANT     302    302       G -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045462.
FT   VARIANT     302    302       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006035.
FT   VARIANT     303    303       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045463.
FT   VARIANT     303    303       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045464.
FT   VARIANT     303    303       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045465.
FT   VARIANT     303    303       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045466.
FT   VARIANT     304    304       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045467.
FT   VARIANT     304    304       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045468.
FT   VARIANT     304    304       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045469.
FT   VARIANT     304    304       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047209.
FT   VARIANT     305    305       K -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045470.
FT   VARIANT     305    305       K -> M (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045471.
FT   VARIANT     305    305       K -> N (in sporadic cancers; somatic
FT                                mutation; loss of nuclear localization).
FT                                /FTId=VAR_045472.
FT   VARIANT     305    305       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045473.
FT   VARIANT     305    305       K -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045474.
FT   VARIANT     306    306       R -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045475.
FT   VARIANT     306    306       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006036.
FT   VARIANT     307    307       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045476.
FT   VARIANT     307    307       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045477.
FT   VARIANT     307    307       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006037.
FT   VARIANT     308    308       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045478.
FT   VARIANT     308    308       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045479.
FT   VARIANT     309    309       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045480.
FT   VARIANT     309    309       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006038.
FT   VARIANT     310    310       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045481.
FT   VARIANT     310    310       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045482.
FT   VARIANT     311    311       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045483.
FT   VARIANT     311    311       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045484.
FT   VARIANT     311    311       N -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045485.
FT   VARIANT     311    311       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045486.
FT   VARIANT     312    312       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045487.
FT   VARIANT     312    312       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045488.
FT   VARIANT     313    313       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045489.
FT   VARIANT     313    313       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045490.
FT   VARIANT     313    313       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045491.
FT   VARIANT     313    313       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045492.
FT   VARIANT     314    314       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045493.
FT   VARIANT     315    315       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045494.
FT   VARIANT     315    315       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045495.
FT   VARIANT     315    315       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045496.
FT   VARIANT     316    316       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045497.
FT   VARIANT     316    316       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045498.
FT   VARIANT     317    317       Q -> H (in a kidney cancer with no family
FT                                history; germline mutation and in a
FT                                sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045499.
FT   VARIANT     317    317       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045500.
FT   VARIANT     317    317       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047210.
FT   VARIANT     317    317       Q -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045501.
FT   VARIANT     317    317       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045502.
FT   VARIANT     318    318       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045503.
FT   VARIANT     319    319       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045504.
FT   VARIANT     319    319       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045505.
FT   VARIANT     319    319       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045506.
FT   VARIANT     320    320       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045507.
FT   VARIANT     321    321       K -> E (in kidney cancer; germline
FT                                mutation).
FT                                /FTId=VAR_045508.
FT   VARIANT     321    321       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045509.
FT   VARIANT     322    322       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045510.
FT   VARIANT     322    322       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045511.
FT   VARIANT     323    323       L -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045874.
FT   VARIANT     323    323       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045512.
FT   VARIANT     323    323       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045513.
FT   VARIANT     323    323       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045514.
FT   VARIANT     323    323       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047211.
FT   VARIANT     324    324       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045515.
FT   VARIANT     324    324       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045875.
FT   VARIANT     324    324       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045516.
FT   VARIANT     325    325       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045517.
FT   VARIANT     325    325       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045518.
FT   VARIANT     325    325       G -> V (in LFS; germline mutation;
FT                                dbSNP:rs28934271).
FT                                /FTId=VAR_006039.
FT   VARIANT     326    326       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045519.
FT   VARIANT     327    327       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045520.
FT   VARIANT     327    327       Y -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045521.
FT   VARIANT     328    328       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045522.
FT   VARIANT     328    328       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045523.
FT   VARIANT     328    328       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045524.
FT   VARIANT     329    329       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045525.
FT   VARIANT     329    329       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045526.
FT   VARIANT     330    330       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045527.
FT   VARIANT     330    330       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047212.
FT   VARIANT     330    330       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045528.
FT   VARIANT     331    331       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045529.
FT   VARIANT     331    331       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045530.
FT   VARIANT     331    331       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045531.
FT   VARIANT     332    332       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045532.
FT   VARIANT     334    334       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006040.
FT   VARIANT     334    334       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045533.
FT   VARIANT     335    335       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045534.
FT   VARIANT     335    335       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045535.
FT   VARIANT     335    335       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045536.
FT   VARIANT     337    337       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006041.
FT   VARIANT     337    337       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_035016.
FT   VARIANT     337    337       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045537.
FT   VARIANT     337    337       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045538.
FT   VARIANT     338    338       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045539.
FT   VARIANT     338    338       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045540.
FT   VARIANT     339    339       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                /FTId=VAR_022316.
FT   VARIANT     339    339       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045541.
FT   VARIANT     341    341       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045542.
FT   VARIANT     342    342       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045543.
FT   VARIANT     342    342       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045544.
FT   VARIANT     342    342       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047213.
FT   VARIANT     343    343       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045545.
FT   VARIANT     344    344       L -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045546.
FT   VARIANT     344    344       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045547.
FT   VARIANT     346    346       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045548.
FT   VARIANT     347    347       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045549.
FT   VARIANT     347    347       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045550.
FT   VARIANT     348    348       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045551.
FT   VARIANT     348    348       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045552.
FT   VARIANT     349    349       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045553.
FT   VARIANT     352    352       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045554.
FT   VARIANT     353    353       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045555.
FT   VARIANT     354    354       Q -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045556.
FT   VARIANT     354    354       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045557.
FT   VARIANT     354    354       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047214.
FT   VARIANT     356    356       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045558.
FT   VARIANT     356    356       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045559.
FT   VARIANT     358    358       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045560.
FT   VARIANT     358    358       E -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045561.
FT   VARIANT     360    360       G -> A (in dbSNP:rs35993958).
FT                                /FTId=VAR_045562.
FT   VARIANT     360    360       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045563.
FT   VARIANT     363    363       R -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045564.
FT   VARIANT     364    364       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045565.
FT   VARIANT     364    364       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045566.
FT   VARIANT     364    364       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045567.
FT   VARIANT     365    365       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047215.
FT   VARIANT     365    365       H -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_045568.
FT   VARIANT     366    366       S -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs17881470).
FT                                /FTId=VAR_022317.
FT   VARIANT     370    370       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045569.
FT   VARIANT     376    376       S -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045570.
FT   VARIANT     376    376       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045571.
FT   VARIANT     379    379       R -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045572.
FT   VARIANT     385    385       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045573.
FT   VARIANT     389    389       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045574.
FT   VARIANT     392    392       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045575.
FT   MUTAGEN      15     15       S->A: Loss of interaction with PPP2R5C,
FT                                PPP2CA AND PPP2R1A.
FT   MUTAGEN      18     18       T->A: No effect on interaction with MDM2
FT                                and increase in protein levels after DNA
FT                                damage.
FT   MUTAGEN      20     20       S->A: Abolishes phosphorylation site.
FT                                Abolishes increase in protein levels
FT                                after DNA damage.
FT   MUTAGEN      20     20       S->D: Constitutively increased TP53
FT                                protein levels.
FT   MUTAGEN      22     23       LW->QS: Loss of interaction with MDM2,
FT                                leading to constitutively increased TP53
FT                                protein levels.
FT   MUTAGEN      37     37       S->D: Abolihes phosphorylation by
FT                                MAPKAPK5.
FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by DYRK2
FT                                and HIPK2 and acetylation of K-382 by
FT                                CREBBP.
FT   MUTAGEN      46     46       Missing: Alters interaction with WWOX.
FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
FT   MUTAGEN     183    183       S->A: Abolishes strongly phosphorylation.
FT   MUTAGEN     183    183       S->E: Inhibits slightly its
FT                                transcriptional activity.
FT   MUTAGEN     248    248       R->S: Does not induce SNAI1 degradation.
FT   MUTAGEN     269    269       S->A: Abolishes phosphorylation.
FT   MUTAGEN     269    269       S->E: Inhibits strongly its
FT                                transcriptional activity.
FT   MUTAGEN     284    284       T->E: Inhibits strongly its
FT                                transcriptional activity.
FT   MUTAGEN     291    292       KK->RR: Abolishes polyubiquitination by
FT                                MKRN1.
FT   MUTAGEN     319    319       K->A: Loss of nuclear localization; when
FT                                associated with A-320 and A-321.
FT   MUTAGEN     320    320       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-321.
FT   MUTAGEN     321    321       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-320.
FT   MUTAGEN     359    359       P->D: Abolishes binding to USP7.
FT   MUTAGEN     361    361       G->E: Abolishes binding to USP7.
FT   MUTAGEN     362    362       S->A: Abolishes binding to USP7.
FT   MUTAGEN     370    370       K->R: Induces a decrease in methylation
FT                                by SMYD2.
FT   MUTAGEN     372    372       K->R: Induces a decrease in protein
FT                                stabilization.
FT   MUTAGEN     373    373       K->R: Abolishes dimethylation by EHMT1
FT                                and EHMT2.
FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
FT   MUTAGEN     382    382       K->R: Abolishes monomethylation by SETD8.
FT   MUTAGEN     383    383       L->A: Abolishes S-315 phosphorylation by
FT                                CDK2/cyclin A.
FT   MUTAGEN     385    385       F->A: Reduced SUMO1 conjugation.
FT   MUTAGEN     386    386       K->A: Abolishes SUMO1 conjugation, in
FT                                vitro and in vivo.
FT   MUTAGEN     387    387       T->A: No effect SUMO1 conjugation.
FT   MUTAGEN     388    388       E->A: Abolishes SUMO1 conjugation.
FT   HELIX        19     23
FT   STRAND       27     29
FT   STRAND       33     35
FT   HELIX        36     38
FT   HELIX        41     44
FT   HELIX        47     55
FT   TURN        105    108
FT   STRAND      110    112
FT   STRAND      118    120
FT   TURN        121    123
FT   STRAND      124    127
FT   TURN        128    131
FT   STRAND      132    135
FT   STRAND      141    146
FT   STRAND      156    165
FT   HELIX       166    168
FT   HELIX       177    180
FT   STRAND      181    183
FT   STRAND      187    189
FT   STRAND      194    199
FT   STRAND      204    207
FT   TURN        209    211
FT   STRAND      214    219
FT   TURN        225    227
FT   STRAND      228    236
FT   HELIX       240    242
FT   TURN        243    248
FT   STRAND      251    258
FT   STRAND      260    262
FT   STRAND      264    274
FT   HELIX       278    287
FT   HELIX       288    290
FT   HELIX       321    324
FT   STRAND      327    334
FT   HELIX       335    354
FT   HELIX       375    380
FT   TURN        382    385
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   P53_RAT                 Reviewed;         391 AA.
AC   P10361; O09168; Q4KMA9; Q66HM0;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   29-MAY-2013, entry version 155.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=Tp53; Synonyms=P53;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3060862; DOI=10.1093/nar/16.23.11384;
RA   Soussi T.;
RT   "Nucleotide sequence of a cDNA encoding the rat p53 nuclear
RT   oncoprotein.";
RL   Nucleic Acids Res. 16:11384-11384(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8441680; DOI=10.1093/nar/21.3.713;
RA   Hulla J.E., Schneider R.P.;
RT   "Structure of the rat p53 tumor suppressor gene.";
RL   Nucleic Acids Res. 21:713-717(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9278438; DOI=10.1074/jbc.272.36.22776;
RA   Mathupala S.P., Heese C., Pedersen P.L.;
RT   "Glucose catabolism in cancer cells. The type II hexokinase promoter
RT   contains functionally active response elements for the tumor
RT   suppressor p53.";
RL   J. Biol. Chem. 272:22776-22780(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart, and Thymus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH HSP90AB1.
RC   TISSUE=Embryo;
RX   PubMed=8663025; DOI=10.1074/jbc.271.25.15084;
RA   Sepehrnia B., Paz I.B., Dasgupta G., Momand J.;
RT   "Heat shock protein 84 forms a complex with mutant p53 protein
RT   predominantly within a cytoplasmic compartment of the cell.";
RL   J. Biol. Chem. 271:15084-15090(1996).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation (By similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per subunit (By similarity).
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       BANP. Interacts with ARMD10, E4F1, CDKN2AIP, NUAK1, UHRF2 and
CC       STK11/LKB1. Interacts with CHD8, leading to recruit histone H1 and
CC       prevent transactivation activity (By similarity). Interacts with
CC       YWHAZ; the interaction enhances TP53 transcriptional activity.
CC       Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction (By
CC       similarity). Interacts with HSP90AB1. Directly interacts with
CC       FBXO42; leading to ubiquitination and degradation of TP53.
CC       Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when
CC       monomethylated at Lys-380) with L3MBTL1. Interacts with GRK5.
CC       Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to
CC       DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB,
CC       UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this
CC       promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this
CC       promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts
CC       with PPIF; the association implicates preferentially tetrameric
CC       TP53, is induced by oxidative stress and is impaired by
CC       cyclosporin A (CsA). Interacts with SNAI1; the interaction induces
CC       SNAI1 degradation via MDM2-mediated ubiquitination and inhibits
CC       SNAI1-induced cell invasion (By similarity). Interacts with KAT6A
CC       (By similarity). Interacts with UBC9 (By similarity). Forms a
CC       complex with UBC9 and PRKRA (By similarity). Interacts with
CC       ZNF385B; the interaction is direct (By similarity).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus (By
CC       similarity). Endoplasmic reticulum (By similarity). Mitochondrion
CC       matrix. Note=Interaction with BANP promotes nuclear localization.
CC       Translocates to mitochondria upon oxidative stress (By
CC       similarity).
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase (By similarity).
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-
CC       18 by VRK1, which may prevent the interaction with MDM2.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Phosphorylated by HIPK1.
CC       Phosphorylated on Ser-390 following UV but not gamma irradiation.
CC       Phosphorylated on Ser-15 upon ultraviolet irradiation; which is
CC       enhanced by interaction with BANP. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, leading to accumulation of p53/TP53, particularly in the
CC       nucleus, thus inducing the transactivation of p53/TP53 target
CC       genes. Phosphorylated at Ser-313 and Ser-390 by CDK2 in response
CC       to DNA-damage (By similarity).
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence (By
CC       similarity).
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-289 and Lys-290, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilize it (By similarity).
CC   -!- PTM: Monomethylated at Lys-370 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       368 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-370
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-368. Dimethylated at Lys-371 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-380 by SETD8, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-368 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity).
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-384 by UBC9 (By
CC       similarity).
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X13058; CAA31457.1; -; mRNA.
DR   EMBL; L07910; AAA41788.1; -; Genomic_DNA.
DR   EMBL; L07904; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07905; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07906; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07907; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07908; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07909; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; U90328; AAB80959.1; -; mRNA.
DR   EMBL; BC081788; AAH81788.2; -; mRNA.
DR   EMBL; BC098663; AAH98663.1; -; mRNA.
DR   IPI; IPI00734784; -.
DR   PIR; S02192; S02192.
DR   RefSeq; NP_112251.2; NM_030989.3.
DR   UniGene; Rn.54443; -.
DR   ProteinModelPortal; P10361; -.
DR   SMR; P10361; 93-288, 317-358.
DR   IntAct; P10361; 2.
DR   MINT; MINT-4651801; -.
DR   STRING; 10116.ENSRNOP00000047840; -.
DR   PhosphoSite; P10361; -.
DR   PaxDb; P10361; -.
DR   PRIDE; P10361; -.
DR   Ensembl; ENSRNOT00000046490; ENSRNOP00000047840; ENSRNOG00000010756.
DR   GeneID; 24842; -.
DR   KEGG; rno:24842; -.
DR   UCSC; RGD:3889; rat.
DR   CTD; 7157; -.
DR   RGD; 3889; Tp53.
DR   eggNOG; NOG80479; -.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P10361; -.
DR   KO; K04451; -.
DR   OMA; SQKTYPG; -.
DR   OrthoDB; EOG45757H; -.
DR   NextBio; 604596; -.
DR   ArrayExpress; P10361; -.
DR   Genevestigator; P10361; -.
DR   GermOnline; ENSRNOG00000010756; Rattus norvegicus.
DR   GO; GO:0000785; C:chromatin; IDA:RGD.
DR   GO; GO:0005829; C:cytosol; IDA:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IBA:RefGenome.
DR   GO; GO:0005667; C:transcription factor complex; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:RefGenome.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:RefGenome.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:RefGenome.
DR   GO; GO:0002039; F:p53 binding; IBA:RefGenome.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IBA:RefGenome.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0071417; P:cellular response to organic nitrogen; IEP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; IBA:RefGenome.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:RefGenome.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IBA:RefGenome.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IBA:RefGenome.
DR   GO; GO:0007275; P:multicellular organismal development; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:RGD.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:RefGenome.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:RGD.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:RefGenome.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IMP:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:RefGenome.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0051453; P:regulation of intracellular pH; IMP:RGD.
DR   GO; GO:0043200; P:response to amino acid stimulus; IEP:RGD.
DR   GO; GO:0031000; P:response to caffeine; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine stimulus; IEP:RGD.
DR   GO; GO:0042493; P:response to drug; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; IBA:RefGenome.
DR   GO; GO:0055093; P:response to hyperoxia; IEP:RGD.
DR   GO; GO:0010038; P:response to metal ion; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0033552; P:response to vitamin B3; IEP:RGD.
DR   GO; GO:0010165; P:response to X-ray; IEP:RGD.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IEP:RGD.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   SUPFAM; SSF47719; p53_tetrameristn; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    391       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185712.
FT   DNA_BIND    100    290       By similarity.
FT   REGION        1     47       Transcription activation (acidic).
FT   REGION       64    108       Interaction with WWOX (By similarity).
FT   REGION       98    368       Interaction with HIPK1 (By similarity).
FT   REGION      111    234       Required for interaction with FBXO42 (By
FT                                similarity).
FT   REGION      114    290       Interaction with AXIN1 (By similarity).
FT   REGION      254    292       Interaction with E4F1 (By similarity).
FT   REGION      271    278       Interaction with DNA (By similarity).
FT   REGION      317    358       Interaction with HIPK2 (By similarity).
FT   REGION      323    354       Oligomerization.
FT   REGION      357    361       Interaction with USP7 (By similarity).
FT   REGION      366    385       Basic (repression of DNA-binding).
FT   MOTIF       303    319       Bipartite nuclear localization signal (By
FT                                similarity).
FT   MOTIF       337    348       Nuclear export signal (By similarity).
FT   MOTIF       368    370       [KR]-[STA]-K motif.
FT   METAL       174    174       Zinc (By similarity).
FT   METAL       177    177       Zinc (By similarity).
FT   METAL       236    236       Zinc (By similarity).
FT   METAL       240    240       Zinc (By similarity).
FT   SITE        118    118       Interaction with DNA (By similarity).
FT   MOD_RES       9      9       Phosphoserine; by HIPK4 (By similarity).
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM (By similarity).
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2
FT                                (By similarity).
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3 (By
FT                                similarity).
FT   MOD_RES      39     39       Phosphoserine; by MAPKAPK5 (By
FT                                similarity).
FT   MOD_RES     118    118       N6-acetyllysine; by KAT6A (By
FT                                similarity).
FT   MOD_RES     181    181       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     267    267       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     282    282       Phosphothreonine; by AURKB (By
FT                                similarity).
FT   MOD_RES     303    303       N6-acetyllysine (By similarity).
FT   MOD_RES     313    313       Phosphoserine; by AURKA, CDK1 and CDK2
FT                                (By similarity).
FT   MOD_RES     368    368       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     368    368       N6-methyllysine; by SMYD2; alternate (By
FT                                similarity).
FT   MOD_RES     370    370       N6-methyllysine; by SETD7 (By
FT                                similarity).
FT   MOD_RES     371    371       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate (By similarity).
FT   MOD_RES     371    371       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     379    379       N6-acetyllysine (By similarity).
FT   MOD_RES     380    380       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     380    380       N6-acetyllysine; by KAT6A; alternate (By
FT                                similarity).
FT   MOD_RES     380    380       N6-methyllysine; by SETD8; alternate (By
FT                                similarity).
FT   MOD_RES     390    390       Phosphoserine; by CK2, CDK2 and NUAK1 (By
FT                                similarity).
FT   CROSSLNK    289    289       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    290    290       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    384    384       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
FT   VARIANT     103    103       G -> S.
FT   VARIANT     256    256       E -> G.
FT   CONFLICT    174    174       C -> W (in Ref. 2; AAA41788).
SQ   SEQUENCE   391 AA;  43451 MW;  E62522313A5C872F CRC64;
     MEDSQSDMSI ELPLSQETFS CLWKLLPPDD ILPTTATGSP NSMEDLFLPQ DVAELLEGPE
     EALQVSAPAA QEPGTEAPAP VAPASATPWP LSSSVPSQKT YQGNYGFHLG FLQSGTAKSV
     MCTYSISLNK LFCQLAKTCP VQLWVTSTPP PGTRVRAMAI YKKSQHMTEV VRRCPHHERC
     SDGDGLAPPQ HLIRVEGNPY AEYLDDRQTF RHSVVVPYEP PEVGSDYTTI HYKYMCNSSC
     MGGMNRRPIL TIITLEDSSG NLLGRDSFEV RVCACPGRDR RTEEENFRKK EEHCPELPPG
     SAKRALPTST SSSPQQKKKP LDGEYFTLKI RGRERFEMFR ELNEALELKD ARAAEESGDS
     RAHSSYPKTK KGQSTSRHKK PMIKKVGPDS D
//
ID   P53_MOUSE               Reviewed;         387 AA.
AC   P02340; Q9QUP3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   18-MAR-2008, sequence version 3.
DT   29-MAY-2013, entry version 172.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=Tp53; Synonyms=P53, Trp53;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6092064;
RA   Bienz B., Zakut-Houri R., Givol D., Oren M.;
RT   "Analysis of the gene coding for the murine cellular tumour antigen
RT   p53.";
RL   EMBO J. 3:2179-2183(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6646235; DOI=10.1038/306594a0;
RA   Zakut-Houri R., Oren M., Bienz B., Lavie V., Hazum S., Givol D.;
RT   "A single gene and a pseudogene for the cellular tumour antigen p53.";
RL   Nature 306:594-597(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6379601; DOI=10.1093/nar/12.14.5609;
RA   Jenkins J.R., Rudge K., Redmond S., Wade-Evans A.;
RT   "Cloning and expression analysis of full length mouse cDNA sequences
RT   encoding the transformation associated protein p53.";
RL   Nucleic Acids Res. 12:5609-5626(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (CLONES PCD53; P53-M11 AND P53-M8).
RX   PubMed=3023970;
RA   Arai N., Nomura D., Yokota K., Wolf D., Brill E., Shohat O.,
RA   Rotter V.;
RT   "Immunologically distinct p53 molecules generated by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 6:3232-3239(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-132.
RX   PubMed=3329909;
RA   Chumakov P.M.;
RT   "Primary structure of DNA complementary to mRNA of murine oncoprotein
RT   p53.";
RL   Bioorg. Khim. 13:1691-1694(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=SCID;
RA   Araki R., Fukumura R., Fujimori A., Tatsumi K., Abe M.;
RT   "Cell cycle in DNA-PKcs knock-out mice.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10403253; DOI=10.1038/21913;
RA   Jimenez G.S., Bryntesson F., Torres-Arzayus M.I., Priestley A.,
RA   Beeche M., Saito S., Sakaguchi K., Appella E., Jeggo P.A.,
RA   Taccioli G.E., Wahl G.M., Hubank M.;
RT   "DNA-dependent protein kinase is not required for the p53-dependent
RT   response to DNA damage.";
RL   Nature 400:81-83(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary carcinoma;
RA   Araki R., Fukumura R., Fujimori A., Tatsumi K., Abe M.;
RT   "Characterization of DNA-PKcs null mutant SX9.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=129/SvJ; TISSUE=Lung fibroblast;
RA   Fujimori A., Abe M.;
RT   "p53 in 129-SVJ mice.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 219-255.
RX   PubMed=1766680;
RA   Burns P.A., Kemp C.J., Gannon J.V., Lane D.P., Bremner R., Balmain A.;
RT   "Loss of heterozygosity and mutational alterations of the p53 gene in
RT   skin tumours of interspecific hybrid mice.";
RL   Oncogene 6:2363-2369(1991).
RN   [12]
RP   DISCOVERY OF P53.
RX   PubMed=221923; DOI=10.1073/pnas.76.5.2420;
RA   DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J.;
RT   "Detection of a transformation-related antigen in chemically induced
RT   sarcomas and other transformed cells of the mouse.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:2420-2424(1979).
RN   [13]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [14]
RP   INTERACTION WITH HIPK1, AND PHOSPHORYLATION.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [15]
RP   INTERACTION WITH AXIN1, AND IDENTIFICATION IN A COMPLEX WITH HIPK2 AND
RP   AXIN1.
RX   PubMed=15526030; DOI=10.1038/sj.emboj.7600475;
RA   Rui Y., Xu Z., Lin S., Li Q., Rui H., Luo W., Zhou H.-M.,
RA   Cheung P.-Y., Wu Z., Ye Z., Li P., Han J., Lin S.-C.;
RT   "Axin stimulates p53 functions by activation of HIPK2 kinase through
RT   multimeric complex formation.";
RL   EMBO J. 23:4583-4594(2004).
RN   [16]
RP   PHOSPHORYLATION AT SER-309 AND SER-386, AND RNA-BINDING.
RX   PubMed=3006031; DOI=10.1073/pnas.83.4.897;
RA   Samad A., Anderson C.W., Carroll R.B.;
RT   "Mapping of phosphomonoester and apparent phosphodiester bonds of the
RT   oncogene product p53 from simian virus 40-transformed 3T3 cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:897-901(1986).
RN   [17]
RP   PHOSPHORYLATION AT SER-386.
RX   PubMed=2145148;
RA   Meek D.W., Simon S., Kikkawa U., Eckhart W.;
RT   "The p53 tumour suppressor protein is phosphorylated at serine 389 by
RT   casein kinase II.";
RL   EMBO J. 9:3253-3260(1990).
RN   [18]
RP   PUTATIVE RNA-BINDING.
RX   PubMed=1406686;
RA   Fontoura B.M., Sorokina E.A., David E., Carroll R.B.;
RT   "p53 is covalently linked to 5.8S rRNA.";
RL   Mol. Cell. Biol. 12:5145-5151(1992).
RN   [19]
RP   DEACETYLATION BY SIRT1.
RX   PubMed=11672522; DOI=10.1016/S0092-8674(01)00524-4;
RA   Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A.,
RA   Guarente L., Gu W.;
RT   "Negative control of p53 by Sir2alpha promotes cell survival under
RT   stress.";
RL   Cell 107:137-148(2001).
RN   [20]
RP   INTERACTION WITH USP7.
RX   PubMed=14719112;
RA   Lim S.-K., Shin J.-M., Kim Y.-S., Baek K.-H.;
RT   "Identification and characterization of murine mHAUSP encoding a
RT   deubiquitinating enzyme that regulates the status of p53
RT   ubiquitination.";
RL   Int. J. Oncol. 24:357-364(2004).
RN   [21]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [22]
RP   INTERACTION WITH BANP.
RX   PubMed=12494467; DOI=10.1002/ijc.10881;
RA   Kaul R., Mukherjee S., Ahmed F., Bhat M.K., Chhipa R., Galande S.,
RA   Chattopadhyay S.;
RT   "Direct interaction with and activation of p53 by SMAR1 retards cell-
RT   cycle progression at G2/M phase and delays tumor growth in mice.";
RL   Int. J. Cancer 103:606-615(2003).
RN   [23]
RP   PHOSPHORYLATION AT SER-15, LYSINE ACETYLATION, UBIQUITINATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15195100; DOI=10.1038/ncb1147;
RA   Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H.,
RA   Pandolfi P.P.;
RT   "PML regulates p53 stability by sequestering Mdm2 to the nucleolus.";
RL   Nat. Cell Biol. 6:665-672(2004).
RN   [24]
RP   PHOSPHORYLATION AT SER-34.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [25]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [26]
RP   INTERACTION WITH CHD8.
RX   PubMed=19151705; DOI=10.1038/ncb1831;
RA   Nishiyama M., Oshikawa K., Tsukada Y.I., Nakagawa T., Iemura S.,
RA   Natsume T., Fan Y., Kikuchi A., Skoultchi A.I., Nakayama K.I.;
RT   "CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment
RT   during early embryogenesis.";
RL   Nat. Cell Biol. 11:172-182(2009).
RN   [27]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [28]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M.,
RA   Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [29]
RP   FUNCTION.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 96-281.
RX   PubMed=11152481; DOI=10.1074/jbc.M011644200;
RA   Zhao K., Chai X., Johnston K., Clements A., Marmorstein R.;
RT   "Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A
RT   resolution.";
RL   J. Biol. Chem. 276:12120-12127(2001).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 92-289.
RX   PubMed=17139084; DOI=10.1107/S090744490603890X;
RA   Ho W.C., Luo C., Zhao K., Chai X., Fitzgerald M.X., Marmorstein R.;
RT   "High-resolution structure of the p53 core domain: implications for
RT   binding small-molecule stabilizing compounds.";
RL   Acta Crystallogr. D 62:1484-1493(2006).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 92-289 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16717092; DOI=10.1074/jbc.M603634200;
RA   Ho W.C., Fitzgerald M.X., Marmorstein R.;
RT   "Structure of the p53 core domain dimer bound to DNA.";
RL   J. Biol. Chem. 281:20494-20502(2006).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 92-284.
RX   PubMed=17876829; DOI=10.1002/prot.21608;
RA   Kwon E., Kim D.Y., Suh S.W., Kim K.K.;
RT   "Crystal structure of the mouse p53 core domain in zinc-free state.";
RL   Proteins 70:280-283(2008).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 93-289 IN COMPLEX WITH DNA,
RP   AND SUBUNIT.
RX   PubMed=18978813; DOI=10.1038/onc.2008.400;
RA   Malecka K.A., Ho W.C., Marmorstein R.;
RT   "Crystal structure of a p53 core tetramer bound to DNA.";
RL   Oncogene 28:325-333(2009).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression (By similarity). Induces the
CC       transcription of long intergenic non-coding RNA p21 (lincRNA-p21)
CC       and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent
CC       transcriptional repression leading to apoptosis, but seems to have
CC       to effect on cell-cycle regulation.
CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58'
CC       inhibits this interaction. Interacts with AURKB, UHRF2 and NOC2L
CC       (By similarity). Interacts with PML (via C-terminus). Interacts
CC       with MDM2; leading to ubiquitination and proteasomal degradation
CC       of TP53. Directly interacts with FBXO42; leading to ubiquitination
CC       and degradation of TP53. Interacts with DAXX. Interacts (when
CC       monomethylated at Lys-376) with L3MBTL1. Interacts with BANP,
CC       CDKN2AIP, NUAK1, STK11/LKB1 and E4F1. Interacts with CHD8, leading
CC       to recruit histone H1 and prevent transactivation activity.
CC       Interacts with AURKA, TRIM24 and BRD7. Interacts with GRK5. Binds
CC       to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA
CC       damage. Interacts with CDK5 in neurons. Phosphorylated at Ser-309
CC       and Ser-386 by CDK2 in response to DNA-damage. Interacts (via N-
CC       terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
CC       Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2.
CC       Interacts with PRKCG. Interacts with PPIF; the association
CC       implicates preferentially tetrameric TP53, is induced by oxidative
CC       stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion (By
CC       similarity). Interacts with KAT6A (By similarity). Interacts with
CC       UBC9 (By similarity). Forms a complex with UBC9 and PRKRA (By
CC       similarity). Interacts with ZNF385B; the interaction is direct (By
CC       similarity).
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=7; IntAct=EBI-474016, EBI-617698;
CC       Q07817-1:BCL2L1 (xeno); NbExp=3; IntAct=EBI-474016, EBI-287195;
CC       P23804:Mdm2; NbExp=3; IntAct=EBI-474016, EBI-641788;
CC       P23804-1:Mdm2; NbExp=2; IntAct=EBI-474016, EBI-3386476;
CC       Q9QUR7:Pin1; NbExp=3; IntAct=EBI-474016, EBI-2432975;
CC       P54099:Polg; NbExp=2; IntAct=EBI-474016, EBI-863636;
CC       Q99KR7:Ppif; NbExp=2; IntAct=EBI-474016, EBI-6455001;
CC       Q61466:Smarcd1; NbExp=4; IntAct=EBI-474016, EBI-371529;
CC       P09671:Sod2; NbExp=2; IntAct=EBI-474016, EBI-1635071;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus (By
CC       similarity). Endoplasmic reticulum (By similarity). Mitochondrion
CC       matrix (By similarity). Note=Interaction with BANP promotes
CC       nuclear localization. Translocates to mitochondria upon oxidative
CC       stress (By similarity).
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase (By similarity).
CC   -!- PTM: Phosphorylated on Ser-15 upon ultraviolet irradiation; which
CC       is enhanced by interaction with BANP (By similarity).
CC       Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1.
CC       Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which
CC       prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3
CC       in response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15 leading to accumulation of p53/TP53, particularly in the
CC       nucleus, thus inducing the transactivation of p53/TP53 target
CC       genes (By similarity). Phosphorylated on Ser-386 following UV but
CC       not gamma irradiation. Phosphorylated by HIPK1.
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-285 and Lys-286, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilize it (By similarity).
CC   -!- PTM: Monomethylated at Lys-366 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       364 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-366
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-364. Dimethylated at Lys-367 EHMT1 and
CC       EHMT2. Monomethylated at Lys-376 SETD8, promoting interaction with
CC       L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-364 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity).
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-380 by UBC9 (By
CC       similarity).
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X00876; CAA25420.1; -; Genomic_DNA.
DR   EMBL; X00877; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00878; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00879; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00880; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00881; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00882; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00883; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00884; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X00885; CAA25420.1; JOINED; Genomic_DNA.
DR   EMBL; X01237; CAA25625.1; -; mRNA.
DR   EMBL; X00741; CAA25323.1; -; mRNA.
DR   EMBL; M13872; AAA39881.1; -; mRNA.
DR   EMBL; M13873; AAA39882.1; -; mRNA.
DR   EMBL; M13874; AAA39883.1; ALT_SEQ; mRNA.
DR   EMBL; AB021961; BAA82344.1; -; mRNA.
DR   EMBL; AF151353; AAD39535.1; -; mRNA.
DR   EMBL; AB017815; BAA82339.1; -; mRNA.
DR   EMBL; AB017816; BAA82340.1; -; mRNA.
DR   EMBL; AB020317; BAA82343.1; -; mRNA.
DR   EMBL; BC005448; AAH05448.1; -; mRNA.
DR   EMBL; S77930; AAB21108.2; -; Genomic_DNA.
DR   IPI; IPI00406306; -.
DR   PIR; A22739; DNMS53.
DR   PIR; S38824; S38824.
DR   RefSeq; NP_001120705.1; NM_001127233.1.
DR   RefSeq; NP_035770.2; NM_011640.3.
DR   UniGene; Mm.222; -.
DR   PDB; 1HU8; X-ray; 2.70 A; A/B/C=96-281.
DR   PDB; 2GEQ; X-ray; 2.30 A; A/B=92-289.
DR   PDB; 2IOI; X-ray; 1.55 A; A=92-289.
DR   PDB; 2IOM; X-ray; 2.00 A; A=92-289.
DR   PDB; 2IOO; X-ray; 2.02 A; A=92-289.
DR   PDB; 2P52; X-ray; 1.50 A; A=92-284.
DR   PDB; 3EXJ; X-ray; 2.00 A; A/B=93-289.
DR   PDB; 3EXL; X-ray; 2.20 A; A=93-289.
DR   PDBsum; 1HU8; -.
DR   PDBsum; 2GEQ; -.
DR   PDBsum; 2IOI; -.
DR   PDBsum; 2IOM; -.
DR   PDBsum; 2IOO; -.
DR   PDBsum; 2P52; -.
DR   PDBsum; 3EXJ; -.
DR   PDBsum; 3EXL; -.
DR   ProteinModelPortal; P02340; -.
DR   SMR; P02340; 88-350.
DR   DIP; DIP-369N; -.
DR   IntAct; P02340; 27.
DR   MINT; MINT-120104; -.
DR   STRING; 10090.ENSMUSP00000104298; -.
DR   PhosphoSite; P02340; -.
DR   PRIDE; P02340; -.
DR   Ensembl; ENSMUST00000005371; ENSMUSP00000005371; ENSMUSG00000059552.
DR   GeneID; 22059; -.
DR   KEGG; mmu:22059; -.
DR   UCSC; uc007jql.2; mouse.
DR   CTD; 22059; -.
DR   MGI; MGI:98834; Trp53.
DR   eggNOG; NOG80479; -.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P02340; -.
DR   KO; K04451; -.
DR   OrthoDB; EOG45757H; -.
DR   ChEMBL; CHEMBL4164; -.
DR   EvolutionaryTrace; P02340; -.
DR   NextBio; 301858; -.
DR   ArrayExpress; P02340; -.
DR   Bgee; P02340; -.
DR   CleanEx; MM_TRP53; -.
DR   Genevestigator; P02340; -.
DR   GermOnline; ENSMUSG00000059552; Mus musculus.
DR   GO; GO:0000785; C:chromatin; IBA:RefGenome.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005657; C:replication fork; IDA:MGI.
DR   GO; GO:0005667; C:transcription factor complex; IBA:RefGenome.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:RefGenome.
DR   GO; GO:0003690; F:double-stranded DNA binding; IBA:RefGenome.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IDA:MGI.
DR   GO; GO:0002039; F:p53 binding; IBA:RefGenome.
DR   GO; GO:0001077; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; IDA:MGI.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:RefGenome.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0002326; P:B cell lineage commitment; IMP:MGI.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IGI:MGI.
DR   GO; GO:0034644; P:cellular response to UV; IGI:MGI.
DR   GO; GO:0007417; P:central nervous system development; IGI:MGI.
DR   GO; GO:0051276; P:chromosome organization; IGI:MGI.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IGI:MGI.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IBA:RefGenome.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IMP:MGI.
DR   GO; GO:0007369; P:gastrulation; IGI:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IGI:MGI.
DR   GO; GO:0006917; P:induction of apoptosis; IDA:MGI.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:BHF-UCL.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IDA:MGI.
DR   GO; GO:0035264; P:multicellular organism growth; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IDA:MGI.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:MGI.
DR   GO; GO:1901525; P:negative regulation of macromitophagy; IMP:MGI.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IGI:MGI.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IMP:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IMP:MGI.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:MGI.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IMP:MGI.
DR   GO; GO:0090343; P:positive regulation of cell aging; IMP:BHF-UCL.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IDA:MGI.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:MGI.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IDA:MGI.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; IGI:MGI.
DR   GO; GO:0034103; P:regulation of tissue remodeling; IMP:MGI.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IDA:MGI.
DR   GO; GO:0042493; P:response to drug; IDA:MGI.
DR   GO; GO:0010332; P:response to gamma radiation; IDA:MGI.
DR   GO; GO:0002931; P:response to ischemia; IMP:MGI.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:MGI.
DR   GO; GO:0009651; P:response to salt stress; IGI:MGI.
DR   GO; GO:0010165; P:response to X-ray; IDA:MGI.
DR   GO; GO:0009303; P:rRNA transcription; IGI:MGI.
DR   GO; GO:0001756; P:somitogenesis; IGI:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IGI:MGI.
DR   GO; GO:0002360; P:T cell lineage commitment; IMP:MGI.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IGI:MGI.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IGI:MGI.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   SUPFAM; SSF47719; p53_tetrameristn; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Apoptosis; Cell cycle;
KW   Complete proteome; Cytoplasm; Disease mutation; DNA-binding;
KW   Endoplasmic reticulum; Isopeptide bond; Metal-binding; Methylation;
KW   Mitochondrion; Necrosis; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Tumor suppressor;
KW   Ubl conjugation; Zinc.
FT   CHAIN         1    387       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185709.
FT   DNA_BIND     96    286       By similarity.
FT   REGION        1     42       Transcription activation (acidic).
FT   REGION       60    104       Interaction with WWOX (By similarity).
FT   REGION       94    364       Interaction with HIPK1.
FT   REGION      107    230       Required for interaction with FBXO42 (By
FT                                similarity).
FT   REGION      110    286       Interaction with AXIN1.
FT   REGION      253    291       Interaction with E4F1 (By similarity).
FT   REGION      267    274       Interaction with DNA.
FT   REGION      313    354       Interaction with HIPK2 (By similarity).
FT   REGION      319    350       Oligomerization.
FT   REGION      353    357       Interaction with USP7 (By similarity).
FT   REGION      362    381       Basic (repression of DNA-binding).
FT   MOTIF       299    315       Bipartite nuclear localization signal (By
FT                                similarity).
FT   MOTIF       333    344       Nuclear export signal (By similarity).
FT   MOTIF       364    366       [KR]-[STA]-K motif.
FT   METAL       170    170       Zinc.
FT   METAL       173    173       Zinc.
FT   METAL       232    232       Zinc.
FT   METAL       236    236       Zinc.
FT   SITE        114    114       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2
FT                                (By similarity).
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3 (By
FT                                similarity).
FT   MOD_RES      34     34       Phosphoserine; by MAPKAPK5.
FT   MOD_RES     114    114       N6-acetyllysine; by KAT6A (By
FT                                similarity).
FT   MOD_RES     177    177       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     263    263       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     278    278       Phosphothreonine; by AURKB (By
FT                                similarity).
FT   MOD_RES     299    299       N6-acetyllysine (By similarity).
FT   MOD_RES     309    309       Phosphoserine; by AURKA, CDK1 and CDK2
FT                                (By similarity).
FT   MOD_RES     364    364       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     364    364       N6-methyllysine; by SMYD2; alternate (By
FT                                similarity).
FT   MOD_RES     366    366       N6-methyllysine; by SETD7 (By
FT                                similarity).
FT   MOD_RES     367    367       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate (By similarity).
FT   MOD_RES     367    367       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     375    375       N6-acetyllysine (By similarity).
FT   MOD_RES     376    376       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     376    376       N6-acetyllysine; by KAT6A; alternate (By
FT                                similarity).
FT   MOD_RES     376    376       N6-methyllysine; by SETD8; alternate (By
FT                                similarity).
FT   MOD_RES     386    386       Phosphoserine; by CK2, CDK2 and NUAK1 (By
FT                                similarity).
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    286    286       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    380    380       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
FT   VARIANT     132    132       A -> V (can cooperate with an activated
FT                                Ras to transform fibroblasts).
FT   VARIANT     165    165       E -> G (in clone P53-M11).
FT   VARIANT     188    188       L -> R.
FT   CONFLICT     45     45       Q -> R (in Ref. 3; CAA25323).
FT   CONFLICT     76     78       PVA -> QW (in Ref. 3; CAA25323).
FT   HELIX        99    101
FT   STRAND      104    106
FT   HELIX       113    116
FT   STRAND      117    121
FT   TURN        122    125
FT   STRAND      126    129
FT   STRAND      134    140
FT   STRAND      150    159
FT   TURN        160    164
FT   HELIX       171    175
FT   STRAND      181    183
FT   STRAND      188    193
FT   STRAND      198    201
FT   TURN        203    205
FT   STRAND      208    213
FT   STRAND      222    230
FT   HELIX       235    237
FT   HELIX       239    242
FT   STRAND      245    252
FT   STRAND      258    268
FT   HELIX       272    283
FT   TURN        285    287
SQ   SEQUENCE   387 AA;  43155 MW;  B55EB7B463E1DD9D CRC64;
     MEESQSDISL ELPLSQETFS GLWKLLPPED ILPSPHCMDD LLLPQDVEEF FEGPSEALRV
     SGAPAAQDPV TETPGPVAPA PATPWPLSSF VPSQKTYQGN YGFHLGFLQS GTAKSVMCTY
     SPPLNKLFCQ LAKTCPVQLW VSATPPAGSR VRAMAIYKKS QHMTEVVRRC PHHERCSDGD
     GLAPPQHLIR VEGNLYPEYL EDRQTFRHSV VVPYEPPEAG SEYTTIHYKY MCNSSCMGGM
     NRRPILTIIT LEDSSGNLLG RDSFEVRVCA CPGRDRRTEE ENFRKKEVLC PELPPGSAKR
     ALPTCTSASP PQKKKPLDGE YFTLKIRGRK RFEMFRELNE ALELKDAHAT EESGDSRAHS
     SYLKTKKGQS TSRHKKTMVK KVGPDSD
//
ID   P53_HORSE               Reviewed;         280 AA.
AC   P79892; Q29481;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   29-MAY-2013, entry version 113.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
DE   Flags: Fragment;
GN   Name=TP53; Synonyms=P53;
OS   Equus caballus (Horse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Perissodactyla; Equidae; Equus.
OX   NCBI_TaxID=9796;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-263.
RC   TISSUE=Spleen;
RX   PubMed=8913276; DOI=10.1016/0304-3835(96)04359-5;
RA   Pazzi K.A., Kraegel S.A., Griffey S.M., Theon A.P., Madewell B.R.;
RT   "Analysis of the equine tumor suppressor gene p53 in the normal horse
RT   and in eight cutaneous squamous cell carcinomas.";
RL   Cancer Lett. 107:125-130(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 76-280.
RX   PubMed=8722575;
RA   Nasir L., Reid S.W.;
RT   "Nucleotide sequence of exons 5 to 9 of the p53 tumour-suppressor gene
RT   of the horse (Equus caballus).";
RL   DNA Seq. 6:185-187(1996).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation (By similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per subunit (By similarity).
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated) with
CC       L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via
CC       N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
CC       Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2.
CC       Interacts with PRKCG. Interacts with PPIF; the association
CC       implicates preferentially tetrameric TP53, is induced by oxidative
CC       stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion (By
CC       similarity). Interacts with KAT6A (By similarity). Interacts with
CC       UBC9 (By similarity). Forms a complex with UBC9 and PRKRA (By
CC       similarity). Interacts with ZNF385B; the interaction is direct (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus (By
CC       similarity). Endoplasmic reticulum (By similarity). Mitochondrion
CC       matrix (By similarity). Note=Interaction with BANP promotes
CC       nuclear localization. Translocates to mitochondria upon oxidative
CC       stress (By similarity).
CC   -!- PTM: Phosphorylated by VRK1, which may prevent the interaction
CC       with MDM2. Phosphorylated by CHEK2 in response to DNA damage,
CC       which prevents ubiquitination by MDM2. Phosphorylated by PLK3 in
CC       response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Probably phosphorylated on by CDK7 in a CAK
CC       complex in response to DNA damage. Phosphorylated by CK2 following
CC       UV but not gamma irradiation. Phosphorylated upon ultraviolet
CC       irradiation; which is enhanced by interaction with BANP.
CC       Stabilized by CDK5-mediated phosphorylation in response to
CC       genotoxic and oxidative stresses at Ser-9, leading to accumulation
CC       of p53/TP53, particularly in the nucleus, thus inducing the
CC       transactivation of p53/TP53 target genes. Phosphorylated by DYRK2
CC       at Ser-9 in response to genotoxic stress. Phosphorylated at Ser-
CC       266 by CDK2 in response to DNA-damage (By similarity).
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence (By
CC       similarity).
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-242 and Lys-243, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilize it (By similarity).
CC   -!- PTM: Monomethylated by SETD7, leading to stabilization and
CC       increased transcriptional activation. Monomethylated by SMYD2,
CC       leading to decreased DNA-binding activity and subsequent
CC       transcriptional regulation activity. Monomethylation by SETD7
CC       prevents interaction with SMYD2 and subsequent monomethylation by
CC       SMYD2 (By similarity). Dimethylated by EHMT1 and EHMT2.
CC       Monomethylated by SETD8, promoting interaction with L3MBTL1 and
CC       leading to repress transcriptional activity. Demethylation by
CC       KDM1A prevents interaction with TP53BP1 and represses TP53-
CC       mediated transcriptional activation (By similarity).
CC   -!- PTM: Sumoylated with SUMO1 (By similarity).
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S83123; AAB46899.1; -; mRNA.
DR   EMBL; U37120; AAB18936.1; -; Genomic_DNA.
DR   UniGene; Eca.16089; -.
DR   UniGene; Eca.21708; -.
DR   ProteinModelPortal; P79892; -.
DR   SMR; P79892; 44-246.
DR   eggNOG; NOG80479; -.
DR   HOVERGEN; HBG005201; -.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-dependent; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Mitochondrion; Necrosis; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN        <1   >280       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185702.
FT   DNA_BIND     52    243       By similarity.
FT   REGION       26     60       Interaction with WWOX (By similarity).
FT   REGION       63    187       Required for interaction with FBXO42 (By
FT                                similarity).
FT   REGION      207    245       Interaction with E4F1 (By similarity).
FT   REGION      224    231       Interaction with DNA (By similarity).
FT   REGION      276   >280       Oligomerization.
FT   MOTIF       256    272       Bipartite nuclear localization signal (By
FT                                similarity).
FT   METAL       126    126       Zinc (By similarity).
FT   METAL       129    129       Zinc (By similarity).
FT   METAL       189    189       Zinc (By similarity).
FT   METAL       193    193       Zinc (By similarity).
FT   SITE         70     70       Interaction with DNA (By similarity).
FT   MOD_RES       9      9       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG (By similarity).
FT   MOD_RES      70     70       N6-acetyllysine; by KAT6A (By
FT                                similarity).
FT   MOD_RES     133    133       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     220    220       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     235    235       Phosphothreonine; by AURKB (By
FT                                similarity).
FT   MOD_RES     256    256       N6-acetyllysine (By similarity).
FT   MOD_RES     266    266       Phosphoserine; by AURKA, CDK1 and CDK2
FT                                (By similarity).
FT   CROSSLNK    242    242       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    243    243       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CONFLICT     79     79       T -> A (in Ref. 2; AAB18936).
FT   CONFLICT     83     83       L -> M (in Ref. 2; AAB18936).
FT   CONFLICT    111    111       A -> V (in Ref. 2; AAB18936).
FT   CONFLICT    138    138       G -> A (in Ref. 2; AAB18936).
FT   NON_TER       1      1
FT   NON_TER     280    280
SQ   SEQUENCE   280 AA;  30985 MW;  040F12030B5ACEE9 CRC64;
     PAVNNLLLSP DVVNWLDEGP DEAPRMPAAP APLAPAPATS WPLSSFVPSQ KTYPGCYGFR
     LGFLNSGTAK SVTCTYSPTL NKLFCQLAKT CPVQLLVSSP PPPGTRVRAM AIYKKSEFMT
     EVVRRCPHHE RCSDSSDGLA PPQHLIRVEG NLRAEYLDDR NTFRHSVVVP YEPPEVGSDC
     TTIHYNFMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG RDRRTEEENF
     RKKEEPCPEP PPRSTKRVLS SNTSSSPPQK KKPLDGEYFT
//
ID   P53_PIG                 Reviewed;         386 AA.
AC   Q9TUB2;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   29-MAY-2013, entry version 131.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10490836; DOI=10.1038/sj.onc.1202870;
RA   Burr P.D., Argyle D.J., Reid S.W.J., Nasir L.;
RT   "Nucleotide sequence of the porcine p53 cDNA, and the detection of
RT   recombinant porcine p53 expressed in vitro with a variety of anti-p53
RT   antibodies.";
RL   Oncogene 18:5005-5009(1999).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage,
CC       thus stopping cell cycle progression. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation (By similarity).
CC   -!- COFACTOR: Binds 1 zinc ion per subunit (By similarity).
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Found in a complex with
CC       CABLES1 and TP73. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. The C-terminus interacts with TAF1, when TAF1 is part
CC       of the TFIID complex. Interacts with HIPK1, HIPK2, AXIN1, and
CC       TP53INP1. Part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with WWOX. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with ARMD10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F1. Interacts with CHD8, leading to
CC       recruit histone H1 and prevent transactivation activity. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional
CC       activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this
CC       interaction. Directly interacts with FBXO42; leading to
CC       ubiquitination and degradation of TP53. Interacts with AURKA,
CC       DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-375)
CC       with L3MBTL1. Interacts with GRK5. Binds to the CAK complex (CDK7,
CC       cyclin H and MAT1) in response to DNA damage. Interacts with CDK5
CC       in neurons. Interacts with AURKB, UHRF2 and NOC2L. Interacts (via
CC       N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2.
CC       Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2.
CC       Interacts with PRKCG. Interacts with PPIF; the association
CC       implicates preferentially tetrameric TP53, is induced by oxidative
CC       stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion (By
CC       similarity). Interacts with KAT6A (By similarity). Interacts with
CC       UBC9 (By similarity). Forms a complex with UBC9 and PRKRA (By
CC       similarity). Interacts with ZNF385B; the interaction is direct (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Nucleus (By
CC       similarity). Endoplasmic reticulum (By similarity). Mitochondrion
CC       matrix (By similarity). Note=Interaction with BANP promotes
CC       nuclear localization. Translocates to mitochondria upon oxidative
CC       stress (By similarity).
CC   -!- DOMAIN: The [KR]-[STA]-K motif is specifically recognized by the
CC       SETD7 methyltransferase (By similarity).
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated on Thr-18 by VRK1, which may prevent
CC       the interaction with MDM2. Phosphorylated on Ser-20 by CHEK2 in
CC       response to DNA damage, which prevents ubiquitination by MDM2.
CC       Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen
CC       species (ROS), promoting p53/TP53-mediated apoptosis.
CC       Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to
CC       DNA damage. Phosphorylated by HIPK1. Phosphorylated on Ser-385
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Stabilized by CDK5-mediated phosphorylation in response
CC       to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-47,
CC       leading to accumulation of p53/TP53, particularly in the nucleus,
CC       thus inducing the transactivation of p53/TP53 target genes.
CC       Phosphorylated by DYRK2 at Ser-47 in response to genotoxic stress.
CC       Phosphorylated at Ser-308 and Ser-385 by CDK2 in response to DNA-
CC       damage (By similarity).
CC   -!- PTM: Acetylated. Its deacetylation by SIRT1 impairs its ability to
CC       induce proapoptotic program and modulate cell senescence (By
CC       similarity).
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation
CC       with MDM2 and may catalyze the formation of short polyubiquitin
CC       chains on p53/TP53 that are not targeted to the proteasome.
CC       Ubiquitinated by MKRN1 at Lys-284 and Lys-285, which leads to
CC       proteasomal degradation. Deubiquitinated by USP10, leading to
CC       stabilize it. Ubiquitinated by TRIM24, which leads to proteasomal
CC       degradation. Ubiquitination by TOPORS induces degradation.
CC       Deubiquitination by USP7, leading to stabilize it (By similarity).
CC   -!- PTM: Monomethylated at Lys-365 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       363 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-365
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-363. Dimethylated at Lys-366 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-375 by SETD8, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Demethylation of dimethylated Lys-363 by KDM1A prevents
CC       interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity).
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-379 by UBC9 (By
CC       similarity).
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety
CC       of transformed cells. p53 is frequently mutated or inactivated in
CC       many types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF098067; AAF04620.1; -; mRNA.
DR   RefSeq; NP_998989.3; NM_213824.3.
DR   UniGene; Ssc.15917; -.
DR   ProteinModelPortal; Q9TUB2; -.
DR   SMR; Q9TUB2; 86-287, 312-353.
DR   STRING; 9823.ENSSSCP00000019016; -.
DR   Ensembl; ENSSSCT00000019534; ENSSSCP00000019016; ENSSSCG00000017950.
DR   GeneID; 397276; -.
DR   KEGG; ssc:397276; -.
DR   CTD; 7157; -.
DR   eggNOG; NOG80479; -.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOGENOM; HOG000039957; -.
DR   HOVERGEN; HBG005201; -.
DR   KO; K04451; -.
DR   OMA; SQKTYPG; -.
DR   OrthoDB; EOG45757H; -.
DR   ArrayExpress; Q9TUB2; -.
DR   GO; GO:0005829; C:cytosol; IEA:Compara.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IEA:Compara.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Compara.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:Compara.
DR   GO; GO:0005657; C:replication fork; IEA:Compara.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IEA:Compara.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IEA:Compara.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; IEA:Compara.
DR   GO; GO:0001077; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; IEA:Compara.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; ISS:UniProtKB.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Compara.
DR   GO; GO:0007569; P:cell aging; ISS:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Compara.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Compara.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Compara.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IEA:Compara.
DR   GO; GO:0034644; P:cellular response to UV; IEA:Compara.
DR   GO; GO:0007417; P:central nervous system development; IEA:Compara.
DR   GO; GO:0051276; P:chromosome organization; IEA:Compara.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Compara.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IEA:Compara.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Compara.
DR   GO; GO:0000733; P:DNA strand renaturation; ISS:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IEA:Compara.
DR   GO; GO:0006983; P:ER overload response; IEA:Compara.
DR   GO; GO:0007369; P:gastrulation; IEA:Compara.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Compara.
DR   GO; GO:0006917; P:induction of apoptosis; IEA:Compara.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Compara.
DR   GO; GO:0071850; P:mitotic cell cycle arrest; IEA:Compara.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Compara.
DR   GO; GO:0007275; P:multicellular organismal development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Compara.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IEA:Compara.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Compara.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Compara.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Compara.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IEA:Compara.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Compara.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IEA:Compara.
DR   GO; GO:0090343; P:positive regulation of cell aging; IEA:Compara.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IEA:Compara.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Compara.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Compara.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Compara.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IEA:Compara.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IEA:Compara.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISS:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; IEA:Compara.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IEA:Compara.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Compara.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; IEA:Compara.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; IEA:Compara.
DR   GO; GO:0090399; P:replicative senescence; IEA:Compara.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Compara.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Compara.
DR   GO; GO:0009651; P:response to salt stress; IEA:Compara.
DR   GO; GO:0010165; P:response to X-ray; IEA:Compara.
DR   GO; GO:0009303; P:rRNA transcription; IEA:Compara.
DR   GO; GO:0001756; P:somitogenesis; IEA:Compara.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Compara.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Compara.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; IEA:Compara.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Compara.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; P53_like_DNA_bnd; 1.
DR   SUPFAM; SSF47719; p53_tetrameristn; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Acetylation; Activator; Apoptosis; Cell cycle; Complete proteome;
KW   Cytoplasm; DNA-binding; Endoplasmic reticulum; Isopeptide bond;
KW   Metal-binding; Methylation; Mitochondrion; Necrosis; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    386       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185710.
FT   DNA_BIND     94    285       By similarity.
FT   REGION        1     45       Transcription activation (acidic).
FT   REGION       63    102       Interaction with WWOX (By similarity).
FT   REGION       92    363       Interaction with HIPK1 (By similarity).
FT   REGION      105    229       Required for interaction with FBXO42 (By
FT                                similarity).
FT   REGION      108    285       Interaction with AXIN1 (By similarity).
FT   REGION      249    287       Interaction with E4F1 (By similarity).
FT   REGION      266    273       Interaction with DNA (By similarity).
FT   REGION      312    353       Interaction with HIPK2 (By similarity).
FT   REGION      318    349       Oligomerization.
FT   REGION      352    356       Interaction with USP7 (By similarity).
FT   REGION      361    380       Basic (repression of DNA-binding).
FT   MOTIF       298    314       Bipartite nuclear localization signal (By
FT                                similarity).
FT   MOTIF       332    343       Nuclear export signal (By similarity).
FT   MOTIF       363    365       [KR]-[STA]-K motif.
FT   METAL       168    168       Zinc (By similarity).
FT   METAL       171    171       Zinc (By similarity).
FT   METAL       231    231       Zinc (By similarity).
FT   METAL       235    235       Zinc (By similarity).
FT   SITE        112    112       Interaction with DNA (By similarity).
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM (By similarity).
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2
FT                                (By similarity).
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3 (By
FT                                similarity).
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7 (By
FT                                similarity).
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5 (By
FT                                similarity).
FT   MOD_RES      47     47       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG (By similarity).
FT   MOD_RES     112    112       N6-acetyllysine; by KAT6A (By
FT                                similarity).
FT   MOD_RES     175    175       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     262    262       Phosphoserine; by AURKB (By similarity).
FT   MOD_RES     277    277       Phosphothreonine; by AURKB (By
FT                                similarity).
FT   MOD_RES     298    298       N6-acetyllysine (By similarity).
FT   MOD_RES     308    308       Phosphoserine; by AURKA, CDK1 and CDK2
FT                                (By similarity).
FT   MOD_RES     363    363       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     363    363       N6-methyllysine; by SMYD2; alternate (By
FT                                similarity).
FT   MOD_RES     365    365       N6-methyllysine; by SETD7 (By
FT                                similarity).
FT   MOD_RES     366    366       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate (By similarity).
FT   MOD_RES     366    366       N6-acetyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     374    374       N6-acetyllysine (By similarity).
FT   MOD_RES     375    375       N6,N6-dimethyllysine; alternate (By
FT                                similarity).
FT   MOD_RES     375    375       N6-acetyllysine; by KAT6A; alternate (By
FT                                similarity).
FT   MOD_RES     375    375       N6-methyllysine; by SETD8; alternate (By
FT                                similarity).
FT   MOD_RES     385    385       Phosphoserine; by CK2, CDK2 and NUAK1 (By
FT                                similarity).
FT   CROSSLNK    284    284       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    285    285       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin) (By
FT                                similarity).
FT   CROSSLNK    379    379       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO) (By
FT                                similarity).
SQ   SEQUENCE   386 AA;  42862 MW;  A4C3D88E8DF55162 CRC64;
     MEESQSELGV EPPLSQETFS DLWKLLPENN LLSSELSLAA VNDLLLSPVT NWLDENPDDA
     SRVPAPPAAT APAPAAPAPA TSWPLSSFVP SQKTYPGSYD FRLGFLHSGT AKSVTCTYSP
     ALNKLFCQLA KTCPVQLWVS SPPPPGTRVR AMAIYKKSEY MTEVVRRCPH HERSSDYSDG
     LAPPQHLIRV EGNLRAEYLD DRNTFRHSVV VPYEPPEVGS DCTTIHYNFM CNSSCMGGMN
     RRPILTIITL EDASGNLLGR NSFEVRVCAC PGRDRRTEEE NFLKKGQSCP EPPPGSTKRA
     LPTSTSSSPV QKKKPLDGEY FTLQIRGRER FEMFRELNDA LELKDAQTAR ESGENRAHSS
     HLKSKKGQSP SRHKKPMFKR EGPDSD
//
ID   PER53_ARATH             Reviewed;         335 AA.
AC   Q42578;
DT   06-DEC-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   01-MAY-2013, entry version 121.
DE   RecName: Full=Peroxidase 53;
DE            Short=Atperox P53;
DE            EC=1.11.1.7;
DE   AltName: Full=ATPA2;
DE   Flags: Precursor;
GN   Name=PER53; Synonyms=P53; OrderedLocusNames=At5g06720;
GN   ORFNames=MPH15.8;
OS   Arabidopsis thaliana (Mouse-ear cress).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
OC   rosids; malvids; Brassicales; Brassicaceae; Camelineae; Arabidopsis.
OX   NCBI_TaxID=3702;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=8977116; DOI=10.1016/S0014-5793(96)01244-6;
RA   Oestergaard L., Abelskov A.K., Mattsson O., Welinder K.G.;
RT   "Structure and organ specificity of an anionic peroxidase from
RT   Arabidopsis thaliana cell suspension culture.";
RL   FEBS Lett. 398:243-247(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Columbia;
RA   Kaneko T., Katoh T., Asamizu E., Sato S., Nakamura Y., Kotani H.,
RA   Tabata S.;
RT   "Structural analysis of Arabidopsis thaliana chromosome 5. XI.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=cv. Columbia;
RG   The Arabidopsis Information Resource (TAIR);
RL   Submitted (APR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=cv. Columbia;
RX   PubMed=14593172; DOI=10.1126/science.1088305;
RA   Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA   Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA   Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA   Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA   Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA   Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA   Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA   Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA   Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA   Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA   Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA   Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT   "Empirical analysis of transcriptional activity in the Arabidopsis
RT   genome.";
RL   Science 302:842-846(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Brover V.V., Troukhan M.E., Alexandrov N.A., Lu Y.-P., Flavell R.B.,
RA   Feldmann K.A.;
RT   "Full-length cDNA from Arabidopsis thaliana.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   CHARACTERIZATION.
RC   STRAIN=cv. Columbia;
RX   PubMed=9738941; DOI=10.1016/S0014-5793(98)00849-7;
RA   Oestergaard L., Pedersen A.G., Jespersen H.M., Brunak S.,
RA   Welinder K.G.;
RT   "Computational analyses and annotations of the Arabidopsis peroxidase
RT   gene family.";
RL   FEBS Lett. 433:98-102(1998).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS).
RC   STRAIN=cv. Columbia;
RX   PubMed=11117266; DOI=10.1023/A:1006442618860;
RA   Oestergaard L., Teilum K., Mirza O., Mattsson O., Petersen M.,
RA   Welinder K.G., Mundy J., Gajhede M., Henriksen A.;
RT   "Arabidopsis ATP A2 peroxidase. Expression and high-resolution
RT   structure of a plant peroxidase with implications for lignification.";
RL   Plant Mol. Biol. 44:231-243(2000).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS).
RC   STRAIN=cv. Columbia;
RX   PubMed=11551197; DOI=10.1021/bi010661o;
RA   Nielsen K.L., Indiani C., Henriksen A., Feis A., Becucci M.,
RA   Gajhede M., Smulevich G., Welinder K.G.;
RT   "Differential activity and structure of highly similar peroxidases.
RT   Spectroscopic, crystallographic, and enzymatic analyses of lignifying
RT   Arabidopsis thaliana peroxidase A2 and horseradish peroxidase A2.";
RL   Biochemistry 40:11013-11021(2001).
RN   [9]
RP   GENE FAMILY ORGANIZATION, AND NOMENCLATURE.
RC   STRAIN=cv. Columbia;
RX   PubMed=12034502; DOI=10.1016/S0378-1119(02)00465-1;
RA   Tognolli M., Penel C., Greppin H., Simon P.;
RT   "Analysis and expression of the class III peroxidase large gene family
RT   in Arabidopsis thaliana.";
RL   Gene 288:129-138(2002).
CC   -!- FUNCTION: Removal of H(2)O(2), oxidation of toxic reductants,
CC       biosynthesis and degradation of lignin, suberization, auxin
CC       catabolism, response to environmental stresses such as wounding,
CC       pathogen attack and oxidative stress. These functions might be
CC       dependent on each isozyme/isoform in each plant tissue.
CC   -!- FUNCTION: Closely linked to lignin formation by showing monolignol
CC       substrate specificity.
CC   -!- CATALYTIC ACTIVITY: 2 phenolic donor + H(2)O(2) = 2 phenoxyl
CC       radical of the donor + 2 H(2)O.
CC   -!- COFACTOR: Binds 2 calcium ions per subunit.
CC   -!- COFACTOR: Binds 1 heme B (iron-protoporphyrin IX) group per
CC       subunit.
CC   -!- SUBCELLULAR LOCATION: Secreted (By similarity).
CC   -!- TISSUE SPECIFICITY: Mainly expressed in roots.
CC   -!- MISCELLANEOUS: There are 73 peroxidase genes in A.thaliana.
CC   -!- SIMILARITY: Belongs to the peroxidase family. Classical plant
CC       (class III) peroxidase subfamily.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X99952; CAA68212.1; -; mRNA.
DR   EMBL; AP002032; BAB09806.1; -; Genomic_DNA.
DR   EMBL; CP002688; AED91055.1; -; Genomic_DNA.
DR   EMBL; AY056186; AAL07035.1; -; mRNA.
DR   EMBL; AY096713; AAM20347.1; -; mRNA.
DR   EMBL; AY087674; AAM65211.1; -; mRNA.
DR   IPI; IPI00531924; -.
DR   RefSeq; NP_196290.1; NM_120755.2.
DR   UniGene; At.93; -.
DR   PDB; 1PA2; X-ray; 1.45 A; A=31-335.
DR   PDB; 1QO4; X-ray; 3.00 A; A=31-335.
DR   PDBsum; 1PA2; -.
DR   PDBsum; 1QO4; -.
DR   ProteinModelPortal; Q42578; -.
DR   SMR; Q42578; 31-335.
DR   STRING; 3702.AT5G06720.1-P; -.
DR   PeroxiBase; 219; AtPrx53.
DR   PaxDb; Q42578; -.
DR   PRIDE; Q42578; -.
DR   EnsemblPlants; AT5G06720.1; AT5G06720.1; AT5G06720.
DR   GeneID; 830561; -.
DR   KEGG; ath:AT5G06720; -.
DR   GeneFarm; 1907; 61.
DR   TAIR; At5g06720; -.
DR   eggNOG; NOG310632; -.
DR   HOGENOM; HOG000237557; -.
DR   InParanoid; Q42578; -.
DR   KO; K00430; -.
DR   OMA; CKKVNGS; -.
DR   PhylomeDB; Q42578; -.
DR   ProtClustDB; CLSN2686891; -.
DR   EvolutionaryTrace; Q42578; -.
DR   ArrayExpress; Q42578; -.
DR   Genevestigator; Q42578; -.
DR   GermOnline; AT5G06720; Arabidopsis thaliana.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:TAIR.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004601; F:peroxidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0002215; P:defense response to nematode; IMP:TAIR.
DR   GO; GO:0009908; P:flower development; IMP:TAIR.
DR   GO; GO:0042744; P:hydrogen peroxide catabolic process; IEA:UniProtKB-KW.
DR   InterPro; IPR010255; Haem_peroxidase.
DR   InterPro; IPR002016; Haem_peroxidase_pln/fun/bac.
DR   InterPro; IPR000823; Peroxidase_pln.
DR   InterPro; IPR019794; Peroxidases_AS.
DR   InterPro; IPR019793; Peroxidases_heam-ligand_BS.
DR   Pfam; PF00141; peroxidase; 1.
DR   PRINTS; PR00458; PEROXIDASE.
DR   PRINTS; PR00461; PLPEROXIDASE.
DR   SUPFAM; SSF48113; Peroxidase_super; 1.
DR   PROSITE; PS00435; PEROXIDASE_1; 1.
DR   PROSITE; PS00436; PEROXIDASE_2; 1.
DR   PROSITE; PS50873; PEROXIDASE_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Disulfide bond;
KW   Glycoprotein; Heme; Hydrogen peroxide; Iron; Metal-binding;
KW   Oxidoreductase; Peroxidase; Pyrrolidone carboxylic acid;
KW   Reference proteome; Secreted; Signal.
FT   SIGNAL        1     30       Potential.
FT   CHAIN        31    335       Peroxidase 53.
FT                                /FTId=PRO_0000023718.
FT   ACT_SITE     72     72       Proton acceptor.
FT   METAL        73     73       Calcium 1.
FT   METAL        76     76       Calcium 1; via carbonyl oxygen.
FT   METAL        78     78       Calcium 1; via carbonyl oxygen.
FT   METAL        80     80       Calcium 1.
FT   METAL        82     82       Calcium 1.
FT   METAL       199    199       Iron (heme axial ligand) (By similarity).
FT   METAL       200    200       Calcium 2.
FT   METAL       251    251       Calcium 2.
FT   METAL       254    254       Calcium 2.
FT   METAL       259    259       Calcium 2.
FT   BINDING     169    169       Substrate; via carbonyl oxygen.
FT   SITE         68     68       Transition state stabilizer.
FT   MOD_RES      31     31       Pyrrolidone carboxylic acid.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     43     43       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    165    165       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    177    177       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    215    215       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    227    227       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    241    241       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    297    297       N-linked (GlcNAc...) (Potential).
FT   DISULFID     41    121       By similarity.
FT   DISULFID     74     79       By similarity.
FT   DISULFID    127    329       By similarity.
FT   DISULFID    206    238       By similarity.
FT   CONFLICT     21     21       V -> L (in Ref. 5; AAM65211).
FT   CONFLICT    172    172       I -> V (in Ref. 5; AAM65211).
FT   CONFLICT    180    180       F -> S (in Ref. 5; AAM65211).
FT   CONFLICT    270    270       D -> N (in Ref. 5; AAM65211).
FT   TURN         34     40
FT   HELIX        44     56
FT   HELIX        62     74
FT   TURN         75     77
FT   STRAND       78     81
FT   HELIX        82     84
FT   HELIX        94     96
FT   TURN         98    103
FT   HELIX       107    120
FT   TURN        122    124
FT   HELIX       127    141
FT   HELIX       161    167
FT   HELIX       175    184
FT   HELIX       189    196
FT   HELIX       197    200
FT   STRAND      201    205
FT   HELIX       206    208
FT   HELIX       210    212
FT   HELIX       216    218
FT   STRAND      219    221
FT   HELIX       228    237
FT   STRAND      247    250
FT   STRAND      252    257
FT   HELIX       261    267
FT   HELIX       274    281
FT   HELIX       287    296
FT   HELIX       298    313
FT   STRAND      322    324
SQ   SEQUENCE   335 AA;  34989 MW;  57E375B212F1BC6B CRC64;
     MAVTNLPTCD GLFIISLIVI VSSIFGTSSA QLNATFYSGT CPNASAIVRS TIQQALQSDT
     RIGASLIRLH FHDCFVNGCD ASILLDDTGS IQSEKNAGPN VNSARGFNVV DNIKTALENA
     CPGVVSCSDV LALASEASVS LAGGPSWTVL LGRRDSLTAN LAGANSSIPS PIESLSNITF
     KFSAVGLNTN DLVALSGAHT FGRARCGVFN NRLFNFSGTG NPDPTLNSTL LSTLQQLCPQ
     NGSASTITNL DLSTPDAFDN NYFANLQSND GLLQSDQELF STTGSSTIAI VTSFASNQTL
     FFQAFAQSMI NMGNISPLTG SNGEIRLDCK KVNGS
//
